


# Analyst

rsc.li/analyst



ISSN 0003-2654



ROYAL SOCIETY  
OF CHEMISTRY

Celebrating  
IYPT 2019

## CRITICAL REVIEW

Joanne Macdonald, Felix von Stetten *et al.*

Review: a comprehensive summary of a decade  
development of the recombinase polymerase amplification



Cite this: *Analyst*, 2019, **144**, 31

## Review: a comprehensive summary of a decade development of the recombinase polymerase amplification

Jia Li, <sup>a</sup> Joanne Macdonald <sup>\*b,c</sup> and Felix von Stetten<sup>\*a,d</sup>

Nucleic acid amplification has permeated every field in the life sciences since the introduction of the classic polymerase chain reaction (PCR) method in 1983. Yet, despite its fundamental reach, PCR has been constrained within the walls of a laboratory, due to its requirement for a sophisticated thermocycling machine, limiting external application in low-resource settings. New isothermal amplification strategies are seeking to break through traditional laboratory boundaries by providing nucleic acid replication at constant temperatures. Of these methods, recombinase polymerase amplification (RPA) is one of the fastest developing, experiencing rapid uptake and market, even though it was introduced comparatively late. Critically, RPA's technology potentiates highly accessible and sensitive nucleic acid amplification outside of laboratory, and even self-testing. Here we provide a comprehensive review of the equipment-free simplicity of RPA over its first decade of development. Our review includes key knowledge of RPA technology, such as its reaction components, mechanism, sensitivities and specificities, and distinctive detection methods. The review also provides know-how for developing RPA assays, and information about commercially available RPA reaction kits and accessories. We summarise critical RPA experimental tips and issues available through data mining the published literature, to assist researchers in mastering the RPA reaction. We also outline influential hotspots of RPA development, and conclude with outlooks for future development and implications for eclipsing PCR and further revolutionising the life sciences.

Received 21st August 2018,  
Accepted 8th October 2018

DOI: 10.1039/c8an01621f

rsc.li/analyst

### 1. Introduction and overview

Nucleic acid amplification (NAA) *in vitro*, the artificial replication of genetic material, has infiltrated all areas of life sciences and biotechnology, such as pathogen detection, cancer research, cloning, sequencing, genetic engineering, synthetic biology, genotyping, mutagenesis, forensic identification of crimes, drug discovery, molecular archaeology, food testing, wellness and lifestyle testing *etc.* This explosive revolution began with the invention of the polymerase chain reaction (PCR) by Kary Mullis in 1983.<sup>1</sup> Fundamentally, PCR is a cyclic process that performs exponential amplification from a single nucleic acid molecule to billions of copies *in vitro*, by providing successive temperatures favourable to nucleic acid replica-

tion processes (strand denaturation, primer annealing, and enzymatic extension). Increasing molecular quantities makes the handling and subsequent applications of nucleic acids easier, reducing the requirement for use of toxic radioactive probes to track molecular presence, and spawning immense creativity around applications for use. Yet, as valuable as PCR is, the requirement for a sophisticated thermocycler to provide the cyclic heating and cooling process, has largely bound PCR to implementation within the walls of a laboratory, impeding its application in low-resource settings.

Recent advances in isothermal nucleic acid amplification have provided simplified incubation conditions for artificial nucleic acid replication, requiring only a constant temperature rather than thermocycling. The single temperature incubation reduces equipment requirements, opening new avenues to break through the boundaries of the laboratory and perform amplification in low-resource settings. The elimination of repeated heating and cooling steps also provides a second advantage for low-resource implementation, through reduced amplification times. Faster reactions occur not only because of a reduction in heating and cooling times, but also because multiple molecular reactions can proceed asynchronously rather than being forced to operate sequentially within an arti-

<sup>a</sup>Laboratory for MEMS Applications, IMTEK – Department of Microsystems Engineering, University of Freiburg, Georges-Köhler-Allee 103, 79110 Freiburg, Germany. E-mail: Felix.von.Stetten@Hahn-Schickard.de; Tel: +49 761 203-73243

<sup>b</sup>Inflammation and Healing Research Cluster, Genecology Research Centre, School of Science and Engineering, University of the Sunshine Coast, Qld, Australia. E-mail: jmacdon1@usc.edu.au; Tel: +61 7 5456 5944

<sup>c</sup>Division of Experimental Therapeutics, Columbia University, New York, NY, USA. E-mail: jm2236@columbia.edu

<sup>d</sup>Hahn-Schickard, Georges-Köhler-Allee 103, 79110 Freiburg, Germany




ficial heating and cooling cycle. Since the early 1990s, a plethora of isothermal nucleic acid amplification methods have adopted various reaction mechanisms. The most well-established methods are exemplified by nucleic acid sequence-based amplification (NASBA, also known as transcription mediated amplification, TMA), signal-mediated amplification of ribonucleic acid (RNA) technology (SMART), helicase-dependent amplification (HDA), recombinase polymerase amplification (RPA), rolling circle amplification (RCA), multiple displacement amplification (MDA), loop-mediated isothermal amplification (LAMP) and strand displacement amplification (SDA); readers can refer to details of these methods in a few reviews.<sup>2–5</sup> One technology in particular, recombinase polymerase amplification (RPA), is experiencing rapid development and increasing market share (Fig. 1), despite its comparatively late introduction, due to its simplified equipment requirements and fast reaction times.

RPA was first introduced in 2006 by Niall Armes from ASM Scientific Ltd (Cambridge, United Kingdom, founded by the Wellcome Trust Sanger Institute).<sup>6</sup> Although RPA has not yet occupied a large market share percentage in the isothermal nucleic acid amplification technology (according to the data from the Grand View Research report,<sup>7</sup> Fig. 1A), it is experiencing the most rapid uptake. More than 250 publications about RPA have been published so far, with a consistent increase in RPA publication numbers in the last six years; noticeably, the RPA publication number started growing exponentially from year 2014 (Fig. 1B). Among these publications, five RPA review papers were published in consecutive years from 2014 to 2018, respectively. The review of Zaghoul and El-shahat focuses on the application of RPA for hepatitis C virus diagnosis;<sup>8</sup> the review of Moore and Jaykus emphasises RPA assays developed for the detection of enteric viruses;<sup>9</sup> the reviews of James and Macdonald,<sup>10</sup> Daher *et al.*<sup>11</sup> and Lobato and O'Sullivan<sup>12</sup> describe and summarise the characteristics and strengths for

applications of RPA in point-of-care (POC) diagnostics. In comparison, here we provide a comprehensive review that focuses on the radical properties and development potential of RPA. Beginning with an introduction of the key aspects of RPA technology, namely reaction components and mechanisms. We subsequently provide know-how about developing RPA assays, including design and selection of oligonucleotides (primer, probe and template); the information about commercially available RPA reaction kits and accessories are also provided. For those interested in the technical implementation of RPA, we summarise critical RPA experimental tips and issues available through data mining the published literature to assist researchers better master RPA reaction. This is followed by elucidating the clinical/field performance of RPA *via* collated data such as sensitivity and specificity from RPA literature. We also describe some distinctive RPA detection methods for those who want to detect RPA assay signal using the methods other than the commonly used PCR detection methods. To understand the critical significance of this technology for eclipsing PCR and breaking out of the boundaries of the laboratory walls, we discuss the development hot-spots of RPA, including quantitative RPA, multiplex RPA reaction, mobile RPA diagnostic, integrated RPA assays on microfluidics and one-step RPA assays. Our review then concludes with outlooks of future development of RPA.

## 2. Recombinase polymerase amplification (RPA) reaction

The prominence of RPA as revolutionary method to eclipse PCR stems from its specific reaction components (Table 1) and mechanism. For a successful RPA assay, the nuances are hinged on the intrinsic factors, the design of the primers, probe and nucleic acid template; and are related to the extrin-



**Jia Li**

*Dr Jia Li did her undergraduate degree in the University of Sydney, working on the structure and activity relationship of carborane phosphonium salts for the Boron Neutron Capture Therapy (BNCT). She then went to England for a research project about onco-protein–protein interactions at the University of Leeds. She did her PhD under Dr Joanne Macdonald's supervision at the University of the Sunshine Coast, developing*

*rapid and novel virus detection biosensors towards point-of-care. Afterwards, she has been working as a post-doc in the University of Freiburg under Alexander von Humboldt Fellowship, researching in assay development for micro-total diagnostic systems.*




**Joanne Macdonald**

*Dr Joanne Macdonald's research focuses on the molecular engineering of advanced devices, including a DNA automaton able to play tic-tac-toe against a human opponent, and rapid field-based biosensors for the detection of pathogens. She is an Associate Professor in Molecular Engineering at the University of the Sunshine Coast (QLD, Australia), holds a joint appointment in Clinical Medical Sciences at Columbia University*

*(New York, USA), and is the Chief Technical Officer of the biosensing company BioCifer Pty Ltd. Dr Macdonald received her PhD in Microbiology in 2003 from the University of Queensland, Australia.*



(A) Global isothermal nucleic acid amplification technology (INAAT) market, by technology, 2016 (%)



(B) RPA publication number summary between 2006 and 2017




Fig. 1 Summary of RPA market share and publication numbers from its first introduction. (A): RPA market share percentage in the isothermal nucleic acid amplification technology. Reprinted and reproduced with permission from ref. 7. Copyright 2018 Grand View Research, Inc. (B): RPA publication numbers from year 2006 to 2017 based on collected data from web of science.

sic factors, such as reaction temperature and agitation, tolerability to mismatches, inhibitors and background DNA. In

addition, the nucleic acid labelling during RPA, and RPA amplicon clean-up and post-amplification treatment are also important details for successful RPA detection. This section provides these practical information summarised from the RPA literature to serve as a guideline for RPA assay design. In addition, readers can also get information about commercially available RPA reaction kits and accessories (Tables 2 and 3). At the end, this section elucidates the clinical/field performance of RPA via data mining of RPA literature, which are also succinctly collated (Tables 4 and 5).

## 2.1 Reaction components

The fundamental reaction mechanism of RPA relies on a synthetically engineered adaptation of a natural cellular process called homologous recombination, a key process in DNA metabolism. The standard RPA reaction reagents comprise three key proteins (recombinase, recombinase loading factor and single-stranded binding protein), which subsequently coordinate with ancillary components such as deoxyribonucleic acid (DNA) polymerase, crowding agent, energy/fuel components (e.g. adenosine triphosphate, ATP) and salt molecules to perform the RPA reaction mechanism (Fig. 2).<sup>6</sup> The detailed reaction components, and their typical concentration and function are provided in Table 1:



Felix von Stetten

*Professor Felix von Stetten studied agricultural sciences and biotechnology. He completed his PhD in Microbiology in 1999 from the Technical University of Munich, Germany. Thereafter, he joined in the diagnostic industry, where he was involved in the development of methods for sample preparation, real-time PCR and DNA-arrays. Subsequently, he joined the Laboratory for MEMS Applications at IMTEK,*

*University of Freiburg, where he was involved in lab-on-a-chip research. In 2008, he became head of the Hahn-Schickard Lab-on-a-Chip division. Now he is associate director of the Hahn-Schickard-Institut für Mikroanalysesysteme, and apl. professor at IMTEK, University of Freiburg.*



**Table 1** Summary of RPA reaction components, their typical concentrations and functions

Reaction components	Typical concentration	Functions	Ref.
T4 UvsX protein	120 ng $\mu\text{L}^{-1}$	Recombinase that possesses pairing and strand-transfer activity that is important in genetic recombination, DNA repair and replication (or <i>E. coli</i> RecA; recombinase is a central component in the related processes of recombinational DNA repair and homologous genetic recombination that is the ortholog of the UvsX protein).	13 and 14
T4 UvsY protein	60 ng $\mu\text{L}^{-1}$	Recombinase loading factor that is classified as a recombination-mediator protein that stimulates the single-stranded DNA-dependent ATPase activity of T4 UvsX and lowers the critical concentration of T4 UvsX required for activity.	15
T4 gp32	600 ng $\mu\text{L}^{-1}$	Single-stranded binding (SSB) protein is involved in DNA replication, repair and recombination, and binds preferentially to single-stranded DNA. The T4 UvsX, T4 UvsY and T4 gp32 proteins work co-operatively to initiate the RPA reaction <i>via</i> unwinding, D-loop formation and stabilisation of the DNA template.	16 and 17
<i>Bacillus subtilis</i> DNA polymerase I ( <i>Bsu</i> ) or <i>Staphylococcus aureus</i> polymerase ( <i>Sau</i> )	<i>Bsu</i> : 30 ng $\mu\text{L}^{-1}$ ; <i>Sau</i> : 8.6 or 12.8 $\mu\text{g}$	DNA polymerase synthesises new DNA templates homologous to the target nucleic acid, by extending nucleotide building blocks from the bound primers, complementary to the original target nucleic acid sequence or "template".	18 and 19
Deoxynucleotide triphosphate (dNTP, N = A, T, C, G)	200 $\mu\text{M}$ each	An equimolar solution of dATP, dCTP, dGTP and dTTP are building blocks used by the DNA polymerase to synthesise new templates.	—
Forward and reverse primers	Usually at 420 nM each, but can be varied in the concentration range of 150 nM to 600 nM	Primers are critical to directing the amplification event to the nucleic acid target of interest through homologous binding. After binding, the primers provide the essential 3'-OH for polymerase to perform strand extension.	20
DNA template	—	The oligonucleotide that the primers bind to for the synthesis of exact new oligonucleotides	—
Carbowax20M (a high molecular weight polyethylene glycol (PEG))	PEG 35K (5%)	The crowding reagent is a good mimic of the real biomacromolecules condition <i>in vivo</i> and facilitates amplification, as the crowding agents can enhance the catalytic activity of the enzymes.	6 and 21–24
Dithiothreitol	2 mM	Stabilisation of the enzymes by baring free sulfhydryl groups.	25
Phosphocreatine	50 mM	The three components form the energy-supply system for the activities of the recombinase and the DNA polymerase.	26
Creatine kinase	100 ng $\mu\text{L}^{-1}$		
Adenosine triphosphate (ATP)	3 mM	The two components serve to stabilise and solubilise the DNA in solution.	27 and 28
Tris(hydroxymethyl)aminomethane (Tris)	50 mM (pH 7.9)		
Potassium acetate	100 mM	Acting as a cofactor for the performance of the enzymes. The RPA reaction initiates once the magnesium acetate is added.	20
Magnesium acetate	14 mM		

## 2.2 Mechanism

RPA starts with the binding of the T4 UvsX protein (recombinase), assisted by the T4 UvsY (loading factor), to the primers to form a nucleoprotein filament. The resulting complex searches for homologous sequences in duplex DNA (Fig. 2).<sup>6</sup> Once the homology is located, the complex invades the double-stranded DNA, forming a D-loop structure. One side of the D-loop is double-stranded where the primer hybridises with the template strand, initiating a strand exchange reaction, whereas the other side of the D-loop remains single-stranded – the unwound complementary strand that is stabilised by the SSB proteins (T4 gp32).<sup>29,30</sup> Subsequently, the recombinase disassembles from the nucleoprotein filament and becomes

immediately available to initiate another strand displacement reaction with a new primer. Primer incorporation allows the DNA polymerase (*Bsu* or *Sau*) to initiate the synthesis from the free 3'-OH at the end of the primer. As the polymerisation continues, the two parental strands continue to separate. Incorporation of both forward and reverse primers enables strand synthesis to occur in both directions simultaneously, and ultimately results in the exponential accumulation of amplified duplex DNA, consisting of the sequence between the forward and reverse primers.

During RPA, the formation of the recombinase-primer complex is the rate limiting for the D-loop formation.<sup>29</sup> It was reported that the D-loop formation was most efficient at the stoichiometries at which the T4 UvsX protein fully coated the



Table 2 Summary of commercialised RPA reaction kits by TwistDx™

Product name	Category	Nucleic acid detection	Compatible general detection method	Product information
TwistAmp® Basic	Lyophilised kit	DNA	Gel electrophoresis	The <b>lyophilised kits</b> contain pre-mixed enzymes and reagents necessary for the amplification, the user needs only supply primers and template (and dNTPs for the liquid kits). The <b>RT kits</b> afford one-step RNA amplification, which contain pre-mixed enzymes and reagents necessary for the amplification. The user need only supply primers, template and RNase inhibitor. Recommended for users who want to combine TwistDx's RPA amplification technology with the use of TwistDx's proprietary fluorescent <b>TwistAmp® exo probe</b> in a homogenous format. The <b>lyophilised kits</b> contain pre-mixed enzymes and reagents necessary for the amplification, the user needs only supply primers, probe and template (and dNTPs for the liquid kits). The <b>RT kits</b> afford one-step RNA amplification, which contain pre-mixed enzymes and reagents necessary for the amplification. The user need only supply primers, probe, template and RNase inhibitor. Tailored for users who want to combine TwistDx's amplification technology with an <b>alternative TwistDx reporter probe system</b> – fluorescent <b>TwistAmp® fpg probe</b> other than the TwistAmp® exo probe system in a homogenous format. The kit contains pre-mixed enzymes and reagents necessary for the amplification, the user needs only supply primers, probe, template and RNase inhibitor. Designed for users who want to detect the amplicons based on <b>sandwich assays</b> . The kit contains pre-mixed enzymes and reagents necessary for the amplification, the user need only supply primers, probe and template. The kits contain pre-mixed enzymes, oligos and reagents necessary for detection of specific genes of <i>Listeria monocytogenes</i> and <i>Campylobacter</i> species respectively in less than 10 minutes. User must perform sample preparation. The kits contain pre-mixed enzymes, oligos and reagents necessary, users need only add DNA, with provided buffer and magnesium acetate to the reactions. The kits also feature internal control DNA and probes in the lyophilised pellets, and lysis buffer for a two-step lysis of up to 5 µL of sample. The turn-around time of the <b>Glow kit</b> and the <b>Flow kit</b> are less than 10 minutes and approximately 20 minutes, respectively.
TwistAmp® Basic RT	Lyophilised kit	RNA		
TwistAmp® Liquid Basic	Liquid kit	DNA		
TwistAmp® Liquid Basic RT	Liquid kit	RNA		
TwistAmp® exo	Lyophilised kit	DNA	Real-time fluorogenic probe-based	
TwistAmp® exo RT	Lyophilised kit	RNA		
TwistAmp® Liquid exo	Liquid kit	DNA		
TwistAmp® Liquid exo RT	Liquid kit	RNA		
TwistAmp® fpg	Lyophilised kit	DNA	Real-time and end-point fluorogenic probe-based	
TwistAmp® nfo	Lyophilised kit	DNA	Lateral flow strip	
TwistAmp® exo +ListeriaM	Food safety lyophilised kit	DNA ( <i>Listeria monocytogenes</i> hly gene)	Real-time fluorogenic probe-based	
TwistAmp® exo +Campylobacter		DNA ( <i>Campylobacter</i> species including <i>jejuni</i> and <i>coli</i> )		
TwistGlow® Salmonella	Food safety lyophilised kit	DNA ( <i>Salmonella enterica</i> INVA gene)	Real-time and end-point fluorogenic probe-based	
TwistFlow® Salmonella			Lateral flow strip	

primers but did not bind substantially to the double-stranded DNA.<sup>30</sup> The SSB proteins and the T4 UvsY (together with the ATP) have been shown to be essential for cooperating in strand exchange reaction along with the T4 UvsX protein.<sup>13,30,32</sup> However, the presence of both of these proteins requires a higher concentration of T4 UvsX protein than what is required in the presence of only one of these proteins.<sup>29,33,34</sup> The SSB proteins can stimulate the strand exchange reaction if T4 UvsX degrades.<sup>33</sup> Importantly, the T4 UvsY protein neutralises the competition between the SSB

proteins and the T4 UvsX for binding sites on the primers preventing the SSB from binding the primer from initiating the recombination event.<sup>35</sup> When the primer concentration is low, the SSB proteins inhibits the strand exchange activity of the T4 UvsX protein.<sup>35</sup> However, once the T4 UvsY protein is supplied, the T4 UvsY protein is able to invade the SSB proteins-covered primers to promote the binding of T4 UvsX protein to primers (from a site that is adjacent to the bound T4 UvsY protein), thereby displacing the SSB proteins from the primers.<sup>35</sup>



**Table 3** Summary of commercialised RPA devices and accessories by TwistDx™

Product name	Category	Compatible general detection method	Product information
Twirla™ Portable Mixing Incubator	Device for incubation	Gel electrophoresis and lateral flow strip	Small and portable, and incubates up to 6 RPA reactions at optimal temperature. It can be powered by battery or mains-power <i>via</i> micro USB. Magnetic mixing of RPA reactions is also possible when fitted with <b>Micro Balls</b> (0.2 mL; dispensed with <b>Micro Ball Dispenser</b> ) in the reaction tube.
T8-ISO Instrument	Device for incubation and detection	Real-time	Incubates up to 8 RPA reactions with 2 channel fluorescence detection per tube; the testing temperature range is from 37 °C to 65 °C. It can be powered by mains-power <i>via</i> micro USB or <b>PowerGorilla external battery</b> . Magnetic mixing of RPA reactions is also possible when fitted with <b>Micro Balls</b> (0.2 mL; dispensed with <b>Micro Ball Dispenser</b> ) in the reaction tube. It can also be adapted into a <b>T8-ISO Carry Case</b> when travelling to demanding environments.
T16-ISO Instrument	Device for incubation and detection	Real-time	An advanced version of the T8-ISO Instrument, which incubates up to 16 RPA reactions with 3 channel fluorescence detection per tube.
Milenia HybriDetect 1	Device for lateral flow detection	Lateral flow strip	Single-plex detection designed to detect a biotin and FITC/FAM labelled amplicon. Detection is based on sandwich assay using <b>gold nanoparticles</b> as tracer.
Milenia HybriDetect 2	Device for lateral flow detection	Lateral flow strip	Duplex detection designed to simultaneously detect two amplicons labelled with FITC (or FAM)/biotin and/or FITC (or FAM)/DIG. Detection is based on sandwich assay using <b>gold nanoparticles</b> as tracer.
PCRD Nucleic Acid Detection	Device for lateral flow detection	Lateral flow strip	Duplex detection designed to simultaneously detect two amplicons labelled with DIG/biotin and/or FITC (or FAM)/biotin. Detection is based on sandwich assay using <b>carbon nanoparticles</b> as tracer.
U-Star disposable nucleic acid lateral flow detection units	Device for lateral flow detection	Lateral flow strip	Single-plex detection designed to detect a biotin and FITC (or FAM) labelled amplicon. Detection is based on sandwich assay using <b>carbon nanoparticles</b> as tracer and is <b>performed in an open cartridge</b> .

**Table 4** RPA literature reporting analytical sensitivity nearing the single analyte detection limit

Analyte(s)	Detection method	Limit of detection	Ref.
<i>Bla</i> CTX-M-15 antimicrobial resistance gene	Electrowetting-on-dielectric (EWOD)-based digital droplets end-point fluorescent detection	5.6 fg (~a single DNA copy)	80
RNA polymerase beta subunit (RPOB) gene of <i>Mycobacterium tuberculosis</i>	Electrochemical detection using gold nanoparticles on a solid phase	1 CFU <sup>a</sup>	103
Early secretory antigenic target-6 (ESAT-6) gene of <i>Mycobacterium tuberculosis</i>	Electrochemical detection on a screen-printed carbon electrode (SPCE)	1 CFU <sup>a</sup>	102
Serotype-specific Enteritidis sequence fragment <i>sdfl</i> of <i>Salmonella Enterica</i>	Real-time fluorescent detection	1 CFU <sup>a</sup>	119
Genomic DNA of <i>Plasmodium falciparum</i> 3D7	Real-time waveguide-based detection	<1 parasite per µL	120
<i>Leishmania donovani</i> kinetoplast minicircle DNA	Real-time fluorescent detection	1 cell	121
β-Conglutin for Lup an 1 anaphylactic allergen	(Competitive) lateral flow strip detection	0.17 attomol	39
<i>CeuE</i> gene of <i>Campylobacter jejuni</i> ; <i>hipO</i> gene of <i>Campylobacter coli</i>	Real-time fluorescent detection	1 CFU <sup>a</sup> ml <sup>-1</sup> in pure culture and chicken broth without enrichment	122
Lentiviruses harboring genome fragment of Zika virus	Clustered regularly interspaced short palindromic repeats (CRISPR)-based end-point fluorescent detection	2 attomol L <sup>-1</sup>	123
B1 gene of <i>Toxoplasma gondii</i>	Lateral flow strip detection	0.1 oocyst	71
Small subunit ribosomal RNA (18S RNA) gene of <i>Plasmodium knowlesi</i>	Real-time fluorescent detection	1 plasmid	124
<i>IS6110</i> gene of <i>Mycobacterium tuberculosis</i> H37Rv genomic DNA	Real-time silicon photonic microring-based detection	3.2 genomic DNA copies (= single cell of H37Rv)	113

<sup>a</sup> CFU: colony forming unit.





Table 5 RPA literature describing clinical/field trials

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
Nucleocapsid (N) gene of bovine coronavirus	Real-time fluorescent detection	10 to 100 RNA copies by probit analysis)	16 fecal and 14 nasal swab specimens collected from cattle showing intestinal and/or respiratory manifestations	100%	100%	Real-time RT <sup>q</sup> -PCR	1000 RNA copies	The same	The same	125
Chlamydia trachomatis CDS2 gene	Lateral flow strip detection	5–12 pathogens per reaction	70 self-collected first void morning urine samples from young adults (19 males and 51 females)	83%	100%	Roche Cobas AmpliCor CT assay	—	Higher	The same	92
cAMP factor ( <i>cfb</i> ) gene of Group B Streptococci	Real-time fluorescent detection	98 genome copies	50 vaginal/anal samples collected from women	96%	100%	Real-time PCR	—	Higher	The same	126
DNA target sequence specific to <i>Cryptosporidium</i> spp.	Lateral flow strip detection	100 oocysts per mL stool	A total of 10 human stool samples clinically verified to contain <i>Cryptosporidium</i> by a reference laboratory and 11 stool samples from healthy volunteers presumed to be uninfected	100%	100%	Real-time PCR	—	Lower	The same	127
5'-Untranslated region of Yellow fever virus (YFV)	Real-time fluorescent detection on the tube scanner	44 genomic copies per reaction in YFV RNA extracts; 21 genomic copies per reaction of YFV-spiked human plasma samples	34 samples of monospecific pools of wild-caught mosquitoes collected from Kedougou, southern Senegal	80%	100%	Real-time RT <sup>q</sup> -PCR	8 genomic copies per reaction in YFV RNA extracts	Higher	The same	117
<i>IS6110</i> gene of <i>Mycobacterium tuberculosis</i> (MTB)	Real-time fluorescent detection	6.25 fg	27 RNA samples of mosquito pools	71.4%	100%	Culture	—	Higher	The same	128
<i>IS1081</i> gene of <i>Mycobacterium tuberculosis</i>	Real-time fluorescent detection	20 fg	121 specimens including induced and expectorated sputum ( <i>n</i> = 119) and respiratory washes (bronchial and tracheal, <i>n</i> = 2) collected from a total of 101 tuberculosis suspect cases (no more than 3 specimens/individual were tested)	91.4%	100%	Real-time PCR	10 <sup>2.5</sup> cysts per mL of stool	Higher	The same	129
<i>Giardia</i> beta giardin gene	Lateral flow strip detection	10 <sup>3</sup> –10 <sup>3.5</sup> cysts per mL of stool	104 clinical stool samples	73%	96%	Real-time PCR	10 <sup>2.5</sup> cysts per mL of stool	Higher	Higher	129



Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
<i>IS6110</i> gene of <i>Mycobacterium tuberculosis</i>	Real-time photonic detection	10 <sup>-6</sup> -fold diluted MTB sample	33 clinical samples including 13 smear and culture positive samples and 20 smear and culture negative samples	100%	100%	Conventional microscopy of smear and solid culture	—	The same	The same	130
A highly conserved 3'-untranslated region that cover DENV 1-4	Real-time fluorescent detection	DENV serotype 1: 237 RNA copies; DENV serotype 2: 618 RNA copies; DENV serotype 3: 363 RNA copies; DENV serotype 4: 383 RNA copies	Inactivated DENV 1-4 spiked plasma and 31 DENV positive samples in Kedougou region in Senegal RNA of 90 plasma samples extracted and tested between 2012-2013 by RT-PCR in Bangkok (Thailand) 10 positive and 10 negative human samples	98%	—	Real-time RT <sup>q</sup> -PCR	—	Higher	—	131
47 kDa gene sequence from the Karp strain of <i>Orientia tsutsugamushi</i> (47-RPA) and the 17 kDa gene sequence from the Wilmington strain of <i>Rickettsia typhi</i>	Lateral flow strip detection	47 kDa gene: 53 DNA copies per reaction 17 kDa gene: 20 copies per reaction	—	80%	100%	Real-time PCR	47 kDa gene: 10 DNA copies per reaction	Higher	Higher	95
Ribosomal 18S DNA of <i>Entamoeba histolytica</i>	Lateral flow strip detection	2.5 fg from serial dilutions of pure DNA extracted from parasites; 40 parasites from spiked stool sample 0.23 ng of DNA	32 samples of DNA extracted from clinical samples	100%	100%	Real-time PCR	2.5 fg from serial dilutions of pure DNA extracted from parasites	The same	The same	132
A sequence designed based on ITS sequences of the <i>Madurella mycetomatis</i> type strain CBS 109801	Gel electrophoresis detection	5 genomic copies per reaction of a molecular RNA standard; 15 genomic copies per reaction in EBOV-spiked human plasma samples 100 DNA copies	12 patient biopsy specimens	100%	100%	Conventional PCR	—	The same	The same	133
Ebola virus (EBOV) nucleocapsid sequence	Real-time fluorescent detection	5 genomic copies per reaction of a molecular RNA standard; 15 genomic copies per reaction in EBOV-spiked human plasma samples 100 DNA copies	928 post-mortem swab samples	100%	100%	Real-time RT <sup>q</sup> -PCR	—	The same	The same	134
Orf virus (ORFV) DNA polymerase gene segments	Real-time fluorescent detection	22 samples collected from suspected cases of Orf, 8 nasal swabs collected from experimentally infected sheep and 5 samples obtained from healthy goats	22 samples collected from suspected cases of Orf, 8 nasal swabs collected from experimentally infected sheep and 5 samples obtained from healthy goats	86%	100%	Real-time PCR	—	Higher	The same	135





Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
Leader peptidase A ( <i>LepA</i> ) gene of <i>Streptococcus pneumoniae</i>	Real-time fluorescent detection	4.1 genome equivalents per reaction	15 blood samples including 11 confirmed culture positive and 4 confirmed culture negative for <i>Streptococcus pneumoniae</i>	100%	100%	Real-time PCR	5.1 genome equivalents per reaction	The same	The same	97
Orf virus (ORFV) DNA polymerase gene segments	Lateral flow strip detection	80 copies per reaction of DNA plasmid	24 ORFV-spiked tissues samples, 53 samples collected from goats with suspected ORFV infection, 8 nasal swabs samples and 5 tissues samples from healthy goats	100%	100%	Real-time PCR	—	The same	The same	64
<i>Leishmania donovani</i> (LD) kinetoplast minicircle DNA	Real-time fluorescent detection	100 DNA copies applying the LD DNA linearised plasmid; 1 genomic DNA copy	96 buffy coats and skin biopsies collected from visceral leishmaniasis, asymptomatic and post-kala-azar dermal leishmaniasis	100%	100%	Real-time PCR	—	The same	The same	121
Highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) NSP2 gene	Real-time fluorescent detection	70 RNA copies per reaction	68 tissue samples and 10 serum samples collected from suspected pigs of HP-PRRSV, 35 serum samples and 12 tissue samples collected from healthy pigs	97.6%	100%	Real-time RT <sup>2</sup> -PCR	—	Higher	The same	136
100% conserved sequence of a major capsid protein gene of all cyprinid herpesvirus 3 strains	Gel electrophoresis detection	10 copies of genomic DNA	12 confirmed latently infected fish and 1 confirmed uninfected fish	100%	100%	Real-time PCR	—	Lower	The same	66
cAMP factor (cfb) gene of Group B Streptococci	Real-time fluorescent detection	6.25–12.5 genome equivalents	124 clinical samples	100%	100%	Real-time PCR	3.1–6.25 genome equivalents	The same	The same	137
Non-structure protein 1 (nsP1) of Chikungunya virus (CHIKV)	Real-time fluorescent detection	80 genome copies of extracted RNA from CHIKV isolate LR strain	58 suspect Chikungunya fever cases	100%	100%	Real-time RT <sup>2</sup> -PCR	80 genome copies of extracted RNA from CHIKV isolate LR strain	The same	The same	87
A sequence designed in NS2A region conserved among all Zika virus lineages	Real-time fluorescent detection	21 RNA copies	25 positive and 9 negative urine samples collected during the Zika virus epidemic in Tuparetama, Brazil	92%	100%	Real-time RT <sup>2</sup> -PCR	—	Higher	The same	138



Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
G-protein-coupled chemokine receptor (GPCR) gene of lumpy skin disease virus (LSDV)	Real-time fluorescent detection	100 DNA copies (179 DNA copies by probit analysis)	12 negative skin samples and 22 skin nodules of suspected LSDV-infected cattle collected during the summer of 2012 in Dakahlia Governorate, Egypt	100%	100%	Real-time PCR	37 DNA copies	The same	The same	139
<i>IS900</i> gene of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> (MAP)	Real-time fluorescent detection	16 plasmid copies per $\mu\text{L}$ ; 500 fg genomic DNA/reaction	Archived DNA of MAP positive blood ( $n = 14$ ), faecal sperm ( $n = 18$ ), faecal ( $n = 12$ ) and tissue ( $n = 4$ ) samples and 20 MAP-negative faecal samples	89.5%	—	Real-time PCR	1 plasmid copies per $\mu\text{L}$ ; 50 fg genomic DNA/reaction	Higher	—	140
T1E4 gene of prostate cancer	Real-time fluorescent detection	1000 RNA copies	9 urine samples obtained from prostate cancer and 2 urine samples from healthy individuals	90%	100%	Real-time RT <sup>2</sup> -PCR	—	The same	The same	141
NS1 gene of porcine parvovirus (PPV)	Real-time fluorescent detection	300 DNA copies	101 clinical tissue samples (serum, liver, kidney, lymph node, spleen and duodenum) collected from pig farms with suspected cases of PPV in Gansu province, China, and 27 clinical samples (serum, kidney and duodenum) collected from healthy pigs	94.4%	100%	Real-time PCR	—	Higher	The same	54
Nucleocapsid gene of type 2 porcine reproductive and respiratory syndrome virus (PRRSV)	Real-time fluorescent detection	100 RNA copies (690 RNA copies by probit analysis)	60 clinical samples (lymph node, lung, spleen and liver) collected from diseased pigs suspected of having PRRS from 5 pig farms in Hebei province, China from 2015–2016	100%	100%	Real-time RT <sup>2</sup> -PCR	100 RNA copies	The same	Lower	142
Cytochrome b gene of <i>Theileria annulata</i>	Lateral flow strip detection	2 pg genomic DNA	17 anticoagulated blood samples collected from tropical theileriosis endemic areas in Gansu province, China	100%	100%	Real-time PCR	—	The same	The same	67



Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
pirA-like gene of <i>Vibrio owensii</i>	Real-time fluorescent detection	2 plasmid copies (2.84 plasmid copies by probit analysis)	138 clinical shrimp obtained from immersion bioassay, including 70 shrimp acute hepatopancreatic necrosis disease (AHPND) infected shrimp and 68 non-AHPND infected shrimp	100%	100%	Real-time PCR	—	Lower	Lower	143
rRNA gene of <i>Fasciola hepatica</i>	Gel electrophoresis detection Lateral flow strip detection	1.6 pg $\mu\text{L}^{-1}$ DNA copies 1.0 pg $\mu\text{L}^{-1}$ DNA copies	102 human stool samples selected from banked specimens	87.8%	100%	Real-time PCR	1.6 pg $\mu\text{L}^{-1}$ DNA copies	Lower	The same	144
N gene of pest des petits ruminants virus (PPRV)	Real-time fluorescent detection Lateral flow strip detection	100 plasmid copies 10 plasmid copies	32 clinical samples collected from suspected cases of PPRV in Gansu province, China and 5 samples obtained from healthy sheep	90%	100%	Real-time RT <sup>-</sup> PCR	150 plasmid copies	Higher	The same	145
ITS2 gene of <i>Phytophthora infestans</i>	Real-time fluorescent detection	50 fg $\mu\text{L}^{-1}$ of genomic DNA	24 potato leaf samples collected from fields with and without visible symptoms of late blight infections in New Brunswick and Quebec provinces, Canada, respectively	60%	100%	LAMP	50 fg $\mu\text{L}^{-1}$ of genomic DNA	Higher	Lower	146
ORF2 gene of porcine circovirus type 2 (PCV2)	Real-time fluorescent detection Lateral flow strip detection	100 plasmid copies 100 plasmid copies	65 clinical samples (spleen, inguinal lymph node, tonsil, lung and serum) collected from suspected PCV2 infection pigs from 8 pig farms in Shandong province, China; 37 clinical samples (inguinal lymph node, tonsil, lung and serum) collected from Gansu Province, China, and 10 PCV1 positive samples conserved in the laboratory	100%	100%	Real-time PCR	80 plasmid copies	The same	The same	69



Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
gD gene of pseudorabies virus	Real-time fluorescent detection Lateral flow strip detection	100 DNA copies 160 DNA copies	76 clinical samples (tonsil, heart, spleen, lymph nodes, lung and serum) collected from pig farms in Shandong province, China, and 26 clinical samples (lymph nodes, tonsil and serum) collected from healthy pigs	93.3% 93.3%	100% 100%	Real-time PCR	—	Higher	The same	70
B1 gene of <i>Toxoplasma gondii</i>	Lateral flow strip detection	0.1 oocysts per reaction	35 soil samples and 15 water samples collected from parks, residential areas, schools and gutterways in Lanzhou city, Gansu rovince, China, during August 2016	100%	100%	Nested PCR	1 oocyst/reaction	The same	The same	71
RNA transcript of TMPRSS2:ERG (a fusion gene for prostate cancer)	RPA fluoculation assay	10 <sup>5</sup> RNA copies	Clinical urine specimens from 10 metastatic castration-resistant promising prostate cancer patients and 5 healthy control patients	70%	100%	Conventional RT <sup>2</sup> -PCR	—	The same	The same	101
VP2 gene of porcine parvovirus	Real-time fluorescent detection	100 DNA copies (103 DNA copies by probit analysis)	115 clinical samples (lymph node, lung, spleen, kidney and duodenum collected from pigs with reproductive disorders, diarrhea or respiratory disease in Hebei province, China from 2014 to 2016)	100%	100%	Real-time PCR	100 DNA copies	The same	The same	147
G-protein-coupled chemokine receptor (GPCR) gene of <i>Capripoxvirus</i>	Real-time fluorescent detection Lateral flow strip detection	300 plasmid copies 300 plasmid copies	107 clinical samples (liver, lung, kidney, spleen, skin and blood) collected from 14 suspected sheep and 6 suspected goats in Gansu province which were characterised by pyrexia, excessive salivation and generalised poock lesions in the skin during the period of October 2014 to August 2015	97% 97%	100% 100%	Real-time PCR	—	Higher	The same	148



Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
Nucleocapsid protein gene of canine distemper virus	Real-time fluorescent detection	9.4 RNA copies (31.8 RNA copies by probit analysis)	32 nasal/oropharyngeal swabs collected from 20 dogs of both sexes (various breeds and ages) from the animal hospital of Agricultural University of Hebei and 12 raccoon dogs from the farms in Hebei Province, China from 2014 to 2016	100%	100%	Real-time RT <sup>2</sup> -PCR	94 RNA copies	The same	The same	149
<i>imp</i> gene of <i>Candidatus</i> Phytoplasma oryzae	Real-time fluorescent detection Lateral flow strip detection	1–10 plasmid copies 10–100 plasmid copies	66 Napier grass samples from various geographical locations in western Kenya	100%	57.1%	Real-time PCR	—	Lower	The same	79
<i>imp</i> gene of <i>Candidatus</i> Phytoplasma mali	Real-time fluorescent detection Lateral flow strip detection	10 copies of cloned plasmid 10 copies of cloned plasmid	38 roots of field samples from apple ( <i>Malus domestica</i> ) trees collected in autumn 2014, in spring 2015 and in June 2016 in private orchards or in the experimental field of the Institute for Fruit Growing in Samochevalovichi, Belarus	100%	100%	Real-time PCR	—	The same	The same	72
N gene of rabies	Real-time fluorescent detection	1000 RNA copies per $\mu$ L of strains SAD B19, Bobeat USA and Kelev	A panel of RNA from 33 field samples	97%	—	Real-time PCR	1 RNA copies per $\mu$ L of strains SAD B19, Bobeat USA and Kelev	Higher	—	150
<i>KRAS</i> oncogenic mutation gene G12D on Exon 12	Real-time silicon photonic microring-based detection	1% to 100% of the mutant cells	70 frozen tissues samples from colorectal cancer patients in Bio-Resource Center of Asian Medical Center, including 24 samples with the G12D mutation (34.3%), 26 samples with G13D mutation (37.1%) and 20 samples with no mutation (28.6%)	100%	100%	Conventional PCR	30% to 100% of the mutant cells	Lower	The same	151
<i>KRAS</i> oncogenic mutation genes G13D on Exon 13				100%	100%			Lower	The same	

Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
A consensus region that covers all 7 S-segment clades of Crimean-Congo Hemorrhagic fever virus (CCHFV)	Real-time fluorescent detection	500 RNA copies (251 RNA copies by probit analysis)	21 extracted patient sera samples obtained in relation to outbreaks of CCHFV in 2013–2015 in Tajikistan	88%	100%	Real-time PCR	—	Higher	The same	152
Canine parvovirus 2 (CPV-2) nucleocapsid protein gene	Real-time fluorescent detection	10 copies of recombinant plasmid	91 fecal swab samples collected from the dogs from 2012 to 2016	100%	100%	Real-time PCR	10 copies of recombinant plasmid	The same	The same	153
G gene of bovine ephemeral fever virus (BEFV)	Lateral flow strip detection	8 plasmid copies per reaction (corresponding to 24 RNA copies)	104 clinical blood specimens and 24 tissue samples including 16 lung tissue specimens, 8 lymph gland specimens collected from suspected dairy cattle cases of BEFV infections in eastern China	97.89%	90.91%	Real-time PCR	—	Higher	Higher	74
<i>IS900</i> gene of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i>	Lateral flow strip detection	8 plasmid copies per reaction	320 individual fecal samples collected between September 2016 and September 2017 from 10 different dairy farms located in 10 distinct geographic regions of Shandong province, China	100%	97.63%	Real-time PCR	8 plasmid copies per reaction	The same	Higher	76
<i>Pro</i> FSC771 hypothetical protein gene of <i>Francisella noatunensis</i> subsp. <i>Orientalis</i>	Real-time fluorescent detection	10 plasmid copies (15 plasmid copies by probit analysis)	Samples of spleen ( $n = 78$ ), head kidney ( $n = 78$ ) and water ( $n = 5$ )	100%	84.89%	Real-time PCR	10 plasmid copies (11 plasmid copies by probit analysis)	The same	Higher	154
VP1 gene of Enterovirus 71 subgenotype C4 (EV71-C4)	Real-time fluorescent detection	3.767 log <sub>10</sub> genomic copies (LGC)	Stool samples ( $n = 44$ ) collected in 2017 by Shenzhen Center for Disease Control and Prevention	100%	100%	Real-time PCR	2.026 log <sub>10</sub> genomic copies (LGC)	The same	The same	155
			Stool samples ( $n = 134$ ) collected from patients with suspected hand-foot-mouth disease at the pediatrics department of Zhujiang Hospital (Southern Medical University, Guangzhou, China) in 2009	89.5%	100%			Lower	The same	





Table 5 (Contd.)

Analyte(s)	Detection method	Limit of detection	Clinical/field sample(s)	Clinical sensitivity	Clinical specificity	Benchmark method	Limit of detection of benchmark method	Clinical sensitivity of benchmark method compared to RPA	Clinical specificity of benchmark method compared to RPA	Ref.
56 Kda gene of a Karp-like strain of <i>Orientia tsutsugamushi</i>	Lateral flow strip detection	10 copies (recombinant plasmid); 12 copies of genomic DNA	62 animal (including <i>Apodemus agrarius</i> , <i>Rattus norvegicus</i> , <i>Microtus fortis</i> and <i>Neomys fodiens</i> ) organ samples including 5 infected animals trapped in the wild, 2 infected in the laboratory and 55 uninfected animals trapped in the wild	100%	100%	Real-time PCR	12 copies of genomic DNA	The same	The same	156
23S rRNA gene of <i>Coxiella burnetii</i>	Lateral flow strip detection	10 copies (recombinant plasmid); 7 copies of genomic DNA	DNA of spleens from 9 5-week old C57BL/6 female <i>Coxiella burnetii</i> -infected mice and 9 control PBS-infected mice	100%	100%	Real-time PCR	7 copies of genomic DNA	The same	The same	157

<sup>a</sup> RT: reverse transcription.


### 2.3 Template, primers, probe and their designs

RPA was initially demonstrated to be a nucleic acid amplification method for DNA,<sup>6</sup> later it was shown that RNA also could be the template by addition of reverse transcriptase (*e.g.* Murine Leukemia virus (MuLV) reverse transcriptase) in the same reaction tube.<sup>36</sup> Regardless of nucleic acid template type, the recommended RPA amplicon length should be below 500 nucleotides for efficient amplification. Most published RPA papers have applied amplicon lengths between 100 and 250 nucleotides, which usually incur fast and efficient amplification. However, shorter amplicons (79 nucleotides;<sup>37</sup> 94 nucleotides<sup>38–40</sup> and longer amplicon up to 1500 nucleotides<sup>6</sup> and 1941 nucleotides<sup>41</sup> have also been reported.

Unlike PCR, the length of RPA primers is relatively long (a recommended minimum of 30 nucleotides, but typically between 32 and 35 nucleotides). Shorter PCR primers (typically between 18 and 25 nucleotides) can also be used in the RPA reaction but may decrease the reaction speed and sensitivity.<sup>42</sup> Application of short PCR primers in RPA has been demonstrated by Mayboroda *et al.*,<sup>43</sup> Martorell *et al.*,<sup>37</sup> Wang *et al.*<sup>44</sup> and Fuller *et al.*<sup>45</sup> The latter two authors have shown that the PCR primers used in RPA resulted higher analytical sensitivity of detection compared to their usage in PCR: RPA detected 100 DNA copies of genetically modified GTS 40-3-2 soybean and 3.5 pg of genomic DNA of *Agrobacterium* spp. respectively, while the benchmark method PCR detected 1000 DNA copies and 350 pg of genomic DNA respectively.<sup>44,45</sup>

The company that sells the commercialised RPA reagents, TwistDx™ Ltd (see section 2.4 and Tables 2 and 3 for more details) provides additional probes that can be incorporated during the RPA reaction. The TwistAmp™ exo probe (typically between 46 and 52 nucleotides) and the TwistAmp® fpg probe (typically between 32 and 35 nucleotides) are used for fluorogenic real-time detection (Fig. 3A and B). These two probes are usually labelled with a fluorophore, a quencher (*e.g.* Black Hole Quencher) that is in close proximity to the fluorophore, to temporarily deter the fluorescent signal, and a blocker (*e.g.* C3-spacer, a phosphate, a biotin-TEG or an amine) at the 3'-end serving to prevent polymerase extension from the 3'-end (Fig. 3A and B). The real-time detection is based on cleavage of fluorogenic probes at an abasic site (also known as an apurinic/apyrimidinic site that is a location in DNA (less often in RNA), which has neither a purine nor a pyrimidine base) between the fluorophore and the quencher. The abasic site can either be tetrahydrofuran (THF) or a dSpacer (a derivative of the THF) or a dR group (the deoxyribose of the abasic site *via* a C–O–C linker). The *E. coli* exonuclease III cleaves the TwistAmp™ exo probe at a THF or a dSpacer site, while the glycosylase/lyase *E. coli* fpg cleaves the TwistAmp™ fpg probe at the dR position (Fig. 3A and B). After the enzymatic cleavage, the TwistAmp® exo probe can serve as a forward primer. However, the TwistAmp™ fpg probe cannot serve as a primer due to different catalytic mode (beta-elimination) of the glycosylase/lyase *E. coli* fpg protein, which does not generate an extendable 3'-OH group but a 3'-phosphate group.<sup>46</sup>






**Fig. 2** RPA reaction mechanism. The reaction starts from the binding of the recombinase (T4 UvsX) to the primers with the help of the loading factor (T4 UvsY). This forms a nucleoprotein filament that searches for the homologous sequence in the double-stranded DNA. Once the homology is located, the complex invades the duplex DNA, forming a D-loop structure to initiate a strand exchange reaction while the unwound strand is stabilised by the single-stranded binding proteins (T4 gp32). The recombinase (*Bsu* or *Sau*) disassembles from the nucleoprotein filament once the strand exchange is performed, and will be available for the next pair of primers. Next, the DNA polymerase extends from the 3' end of primers. As the polymerisation continues, the two parental strands begin to separate and eventually form two duplexes, and then the whole process repeats.<sup>31</sup>

A third probe, the TwistAmp™ LF (typically between 46 and 52 nucleotides), is used for lateral flow strip detection (Fig. 3C). This probe is labelled at the 5'-end (e.g. with fluorescein), has a blocker at the 3'-end, and an internal abasic site (THF or dSpacer). The Nfo endonucleases IV cleaves at this abasic site of the TwistAmp™ LF probe, and generates an extendable 3'-OH group for polymerisation. However, unlike the *E. coli* exonuclease III which degrades most of the amplicons during RPA reaction, the Nfo endonuclease IV generates a slower signal and incomplete cleavage to avoid amplicon degradation (also see section 2.8).<sup>46</sup> Therefore, the TwistAmp™ LF probe can also be used for cases when gel electrophoresis (GE) is chosen as a detection method.

To select suitable RPA templates and to design primers and probes, users can refer to the criteria suggested in the TwistAmp™ reaction kit manual.<sup>20</sup> In brief, (1) GC content of the DNA template should be between 40% and 60%, and should avoid long homo-polymer tracks, few direct/inverted repeats and palindromes; (2) GC content of the primers should be between 30% and 70%, and should avoid long tracks of guanines at the 5' end but recommend cytidines; and (3) guanines and cytidines are recommended at 3'-end of the primer for improved performance. From the RPA literature, it

is further recommended that users evaluate the melting temperature, hybridisation stability, secondary structures and dimer formations among these oligonucleotides.<sup>47</sup> Specific softwares such as BioEdit version 7.0.5.3,<sup>48</sup> Primer3,<sup>49</sup> UNAFold,<sup>50</sup> mFOLD,<sup>51</sup> Oligoanalyzer 3.1 (IDT, Leuven, Belgium), PrimerQuest software (Integrated DNA Technologies, Coralville, IA) and Visual OMP (DNA software, MI, USA) have been used in the literature for analysing RPA oligonucleotide properties. An effective way to avoid primer dimer formation is to employ self-avoiding molecular recognition systems (SAMRS), by including SAMRS nucleotides 2-aminopurine-2'-deoxyriboside (A\*), 2'-deoxy-2-thiothymidine (T\*), 2'-deoxyinosine (G\*) and N4-thyl-2'-deoxycytidine (C\*) in the primers.<sup>52</sup> The inclusion of these SAMRS nucleotides strategically replaces the hydrogen-bonding units from natural A pairs with T (and G pairs with C) to SAMRS A\* pairs with natural T, SAMRS T\* pairs with natural A, SAMRS G\* pairs with natural C and SAMRS C\* pairs with natural G. However, the SAMRS A\* and SAMRS G\* nucleotides do not interact with the SAMRS T\* and SAMRS C\* nucleotides respectively no matter what their concentration, and in this way, the undesired products due to primer dimer can be avoided during nucleic acid amplification.<sup>52,53</sup> Such SAMRS system has been demonstrated in RPA





**Fig. 3** RPA probes. A: TwistAmp™ exo probe. This probe is cleaved by the *E. coli* exonuclease III at the abasic site (e.g. tetrahydrofuran, THF) to depart the fluorophore from the quencher and generate an extensible 3'-OH group for polymerisation. B: TwistAmp™ fpg probe. This probe is cleaved by the glycosylase/lyase *E. coli* fpg at the dR position (the deoxyribose of the abasic site *via* a C–O–C linker) to depart the fluorophore from the quencher and generate a 3'-phosphate group which is non-extensible for polymerisation. C: TwistAmp™ LF probe. This probe is cleaved by the *Nfo* endonucleases IV at the abasic site (e.g. tetrahydrofuran, THF) to generate an extensible 3'-OH group for polymerisation. The DNA polymerases extend and displace from 3'-ends of the primers and cleaved probe to produce the minor amplicons (from the forward and reverse primers) and a displaced strand. The displaced strand combines with the labelled reverse primer, and leads to the production of a dual-labelled amplicon (the major amplicon) for the downstream sandwich assay detection.<sup>31</sup>


reaction by Sharma and co-workers, and was shown to successfully eliminate RPA artifacts.<sup>53</sup> In addition, caution is needed to avoid overlap between the primer and probe which has been shown to impede the desired amplification efficiency.<sup>54,55</sup> Collectively speaking, it is sufficient to follow the described guidelines as a starting point for *in silico* optimal design of the RPA oligonucleotide candidates, however, the resulting candidates should be screened through RPA reactions to select the preferred final oligonucleotide set applicable for a specific RPA assay (e.g. TwistDx™ Ltd recommends designing five forward and reverse primers, and 3 probes).

#### 2.4 Commercial kits and instrumentation by TwistDx™

All the RPA reagents are available for commercial purchase through TwistDx™, a subsidiary of Abbott.<sup>56</sup> The company provides various kits for RPA reactions that can be customised towards specific applications by the end user. The company also sells RPA kits for the detection of specific food-borne pathogens (e.g. *Listeria monocytogenes*, *Campylobacter* and *Salmonella enterica*) (Table 2). The company not only provides RPA reagents in liquid format, but also in lyophilised pellet format which allows in-field application. These lyophilised pellets have shelf-lives up to 12 weeks at 25 °C or up to 3 weeks at 45 °C.<sup>57</sup> In addition, TwistDx™ offers a custom freeze-drying service to create RPA reaction pellets containing primers, probes, and concentrations of protein components or other components (e.g. internal control DNA or RNA species), which can be encased in various holding vessels with different volumes.<sup>58</sup>

Apart from various RPA reaction kits, TwistDx™ also develops tailor-made devices and accessories for RPA reactions; these devices and accessories enable incubation, dispensing, mixing, detection, power supply and portability (Table 3 and Fig. 4). The Twirla™ device is a hand-held sized battery-powered incubator, which allows up to six parallel RPA reactions and subsequent end-point detection (e.g. gel electrophoresis and lateral flow strip detection; Fig. 4A) (note that the Twirla™ is an upgraded version of an earlier Twista® device that does not support constant mixing during incubation, which has now been discontinued). Alternatively, the T8-ISO allows up to eight parallel incubations and two-channel real-time fluorescent detection per tube (Fig. 4B). The T16-ISO is an advanced version of the T8-ISO, which supports up to sixteen parallel reactions with three-channel fluorescent detection per tube (Fig. 4C). The T8-ISO and the T16-ISO can be powered by mains-power supply, micro USB, or PowerGorilla external battery (Fig. 4D). Moreover, all three incubators mentioned so far support magnetic mixing (programmed or constant) when fitted with Micro Ball(s) (0.2 mL; dispensed with Micro Ball Dispenser) in the reaction tube (Fig. 4E). For lateral flow strip detection, TwistDx™ provides four different lateral flow devices: Milenia HybriDetect 1, Milenia HybriDetect 2 (Fig. 4F), PCRd Nucleic Acid Detection (Fig. 4G) and U-Star Disposable Nucleic Acid Lateral Flow Detection Units (Fig. 4H). The Milenia HybriDetect 1 and the U-Star Disposable Nucleic Acid Lateral Flow Detection Units allow





**Fig. 4** RPA devices and accessories. (A): Twirla™ Portable Mixing Incubator. (B): T8-ISO Instrument. (C): T16-ISO Instrument. (D): PowerGorilla external battery. (E): Micro Balls (0.2 mL, left) and Micro Ball Dispenser (right). (F): Milenia HybriDetect lateral flow strips. (G): PCRD Nucleic Acid Detection device. (H): U-Star Disposable Nucleic Acid Lateral Flow Detection Units device. Reprinted and reproduced with permission from TwistDx™ Limited. Copyright 2009–2018 TwistDx™ Limited.

single-plex detection while the other two devices allow duplex detection. All the lateral flow devices except for the PCRD Nucleic Acid Detection device are based on sandwich assay using gold nanoparticles as tracer; the PCRD Nucleic Acid Detection device employs carbon nanoparticles, which can be more sensitive than the gold nanoparticles.<sup>59,60</sup> The Milenia HybriDetect are provided as strips, whereas the PCRD Nucleic Acid Detection strips are encased in a semi-sealed cartridge, and the U-Star Disposable Nucleic Acid Lateral Flow Detection strips are embedded in a sealed cartridge designed to enable the RPA reaction to flow to the strips in a completely closed environment that prevents cross-contamination of amplified products.

## 2.5 Influence of temperature and agitation

For RPA reactions to achieve optimal efficiency and analytical sensitivity, the choice of target sequence and the designs of corresponding primers and probe are the intrinsic determinants, however, the reaction temperature and agitation during

RPA reaction are two of the most important contributing extrinsic factors.

The recommended RPA reaction temperature is between 37 °C and 42 °C,<sup>42</sup> and Crannell *et al.*<sup>61</sup> and Wang *et al.*<sup>44</sup> have also demonstrated that RPA reaction can be performed using body temperature, which can be used advantageously for in-field application. However, several research groups have studied RPA reaction temperatures that lie outside of the recommended range.<sup>38,44,45,60,62–78</sup> The largest temperature range was tested between 15 °C and 50 °C,<sup>62,64,69,70,76</sup> and results indicated the marginal reaction temperature to produce a positive result should be greater than 30 °C.<sup>62–64,66,67,69,71,74,76,77</sup> However, Sun *et al.*<sup>65</sup> and Poulton and Webster<sup>60</sup> showed that temperature as low as 25 °C could still generate a positive signal after RPA amplification and subsequent lateral flow strip detection. Moreover, Lillis *et al.*<sup>63</sup> showed that the ambient temperature also had an effect on RPA reaction: the RPA reaction was unstable if the ambient temperature was below 10 °C, however, extension of the reaction time could improve positive results attainability. Such reaction tempera-



ture range studies indicate that RPA reaction does not require precise temperature control.

While reaction temperature provides a suitable working environment for the RPA enzymes, agitation increases the interactions among the RPA components in a homogenous reaction solution. TwistDx™ recommends the user performing two times mixing steps for the RPA reaction, one is at the beginning of the process and the other is after 4 minutes of the reaction. The former is to mix all the RPA reagents to initiate the reaction, the latter is to prevent from local depletion of the reaction reagents, thereby increasing the reaction rate. Wambua *et al.*<sup>79</sup> reported that threshold fluorescence values were reached in 5–8 minutes when agitation was performed after 4 minutes, whereas the time to reach detectable levels ranged between 8 and 14 minutes without this agitation. In addition, constant shaking throughout the RPA reaction has been shown to further accelerate the RPA reaction rate, achieve more stable positive results and improve sensitivity, especially when the template concentration is close to the limit of detection.<sup>57,62,80</sup> Kersting *et al.*<sup>62</sup> reported that constant shaking resulted in faster and more stable signals on the lateral flow strips than with the recommended two-shaking event. Kalsi *et al.*<sup>80</sup> also reported that continuous mixing of microdroplets from a RPA exo assay led to faster time to result, increased fluorescence and improved sensitivity. In addition, Moody *et al.*<sup>81</sup> built up a mathematical model and showed that mechanical stirring is better than manually shaking to eliminate inter-operator variations and obtain consistent quantitative experimental result; yet the ideal mixing frequency is assay dependent, and should be determined prior to the reaction.<sup>57,81</sup> Nevertheless, if a shaking condition is not available, Lillis *et al.*<sup>57</sup> demonstrated that a decrease of the reaction volume (*e.g.* from 50  $\mu\text{L}$  to 5  $\mu\text{L}$ ) could compensate for the shaking effect, as smaller volume increased interactions between the reagents and oligonucleotides required for the amplification.

## 2.6 Tolerability to mismatches, inhibitors and background DNA

Apart from temperature and agitation, tolerability to mismatches, inhibitors and background DNA are other vital factors for efficient and sensitive RPA reaction. RPA has the ability to tolerate mismatches, and the highest mismatch tolerability reported so far is nine nucleotide base pairs across the primer and probe binding sites.<sup>82–89</sup> Studies also showed that the mismatches at the 5'-end or centre of primers only mildly affect the RPA reaction, but mismatches located at the 3'-end of primers significantly affect the reaction.<sup>84,86</sup> This is consistent with the RPA reaction mechanism (see section 2.2), since the polymerase extends the primers and probe (once cleaved) from the 3'-terminus. A useful application for such mismatch sensitivity at the 3'-end is to distinguish single nucleotide polymorphism (SNP). Yamanaka *et al.*<sup>90</sup> applied this property to differentiate polymorphisms for the tobacco use disorder genes; the DNA polymerase extension was efficient when the 3'-terminal base of a primer matched its target, whereas the

DNA polymerase extension was inefficient or non-existent when the 3'-terminal base was mismatched.<sup>90</sup> However, of the general RPA mismatch tolerability (outside of the 3'-end of the primer) can be advantageous, as it enables some flexibility in primer design for highly polymorphic targets, where long conserved target regions are hard to locate. Conversely, the drawback of such mismatch tolerability is a tendency towards non-specific detection of closely-related species. Indeed, non-specific detections have been observed by Patel *et al.*,<sup>87</sup> Moore *et al.*<sup>88</sup> and Yang *et al.*<sup>69</sup> when detecting chikungunya virus, epidemic human noroviruses and porcine circovirus Type 2, respectively.

When testing clinical or field samples, numerous substances (*e.g.* inhibitors) are either present or could be introduced during sample preparation and processing steps, which can potentially interfere with nucleic acid amplification. RPA has been demonstrated to tolerate certain (PCR) inhibitors, including: (1) haemoglobin (20  $\text{g L}^{-1}$ ), heparin (0.5 U) and urine (1.25%) showed no effect on RPA reaction;<sup>62,91</sup> and (2) haemoglobin (50  $\text{g L}^{-1}$ ), ethanol (4% v/v) and urine (up to 5%), which only slightly affected reactions.<sup>62,91,92</sup> However, RPA reaction was totally inhibited in the presence of SDS (0.05% v/v) and urine (10%).<sup>62,91</sup> It was also observed that RPA reactions were more susceptible to inhibitors when the DNA template concentration was close to the limit of detection.<sup>62,91</sup> However, it is also important to carefully consider the choice of extraction buffer or incubation medium for the sample preparation and processing steps, as these working solutions may also contain potential inhibitors. For example, Valasevich and Schneider<sup>72</sup> found that Cetyltrimethyl ammonium bromide (CTAB) DNA extraction buffer strongly inhibited RPA reaction. Similarly, Liu *et al.*<sup>93</sup> found that selenite cystine broth (bacterial enrichment medium) significantly affected RPA reactions, resulting in a large number of primer dimers that led to false positive results on the lateral flow strip detection.

In addition to tolerating inhibitors, RPA is capable of amplifying target nucleic acids in the presence of background DNA.<sup>94–97</sup> However, similar to the tolerability for inhibitors, the tolerability for background DNA is also concentration dependent. Clancy *et al.*<sup>97</sup> observed that the RPA reaction was significantly inhibited when 400 ng of background human DNA was present, but was much less inhibited when 200 ng of background human DNA was present. Rohrman and Richards-Kortum<sup>94</sup> showed that RPA was completely inhibited by 0.5  $\mu\text{g}$  of sheared salmon sperm DNA when 50 copies of human immunodeficiency virus-1 (HIV-1) target DNA were present, while only inhibited by 2 or 5  $\mu\text{g}$  of sheared salmon sperm DNA when  $10^3$  or  $10^6$  copies of the target DNA were present respectively. In addition, Rohrman and Richards-Kortum<sup>94</sup> also pointed out that the primer, probe and target sequences used in the assay could influence the maximum background DNA concentration tolerability. Both HIV-1 and *Plasmodium falciparum* RPA assays were completely inhibited by 2  $\mu\text{g}$  of sheared salmon sperm DNA respectively when  $10^3$  copies of HIV-1 and *Plasmodium falciparum* target DNAs were present.<sup>94</sup> However, when the same amount of target DNA were present



( $10^3$  copies), the *Entamoeba histolytica* and *Giardia duodenalis* assays were completely inhibited only by 1 and 0.5  $\mu\text{g}$  of sheared salmon sperm DNA, respectively.<sup>94</sup>

## 2.7 Nucleic acid labelling during RPA

One vital process for diverse down-stream RPA applications (e.g. lateral flow strip detection and enzyme-linked immunosorbent assay) is to incorporate labels into nucleic acid template during RPA reaction, so that the incorporated labels allow capture, detection and/or assist the signal generation of RPA assays. Such nucleic acid labelling can be achieved terminally using 5'-labelled primers or internally *via* labelled nucleotides.<sup>39,40,98–104</sup> The labels used for nucleic acid labelling can be fluorescent entity (e.g. fluorescein), ligand (e.g. biotin) or even a short segment of nucleotides (overhang). Most terminal nucleic acid labelling using RPA employs both 5'-labelled forward and backward primers, such that the amplicons possess dual-labels that can be captured and detected by corresponding recognition molecules in down-stream assays. However, RPA only tolerates to certain labels *via* 5'-labelling process. Crannell *et al.*<sup>105</sup> reported a failure of RPA incorporation of five different 5'-labels (Cy5, Cy3, bromodeoxyuridine, tetrachlorofluorescein and hexachlorofluorescein) compared to successful incorporation with three 5'-labels, Alexa Fluor488, fluorescein and digoxigenin.

For internal nucleic acid labelling during RPA, the reaction mixture can be supplemented with labelled nucleotides, mostly using digoxigenin-dUTPs, which randomly substitute dTTPs during polymerase extension to create labelled amplicons.<sup>101–104</sup> In comparison to the terminal labelling, the internal labelling allows more labels to be incorporated into a single nucleic acid template, thus having more binding opportunities in down-stream assays. However, terminal labelling can be a better choice when the down-stream application is for a sandwich assay, as the two labels incorporated *via* terminal labelling are further apart (separated by the length of amplicon), which could prevent steric hindrance of binding if the labels were too close together.

## 2.8 Amplicon clean-up and post-amplification treatment


The above-mentioned issues have considered the conditions both before and during RPA reactions. In addition, post-reaction procedures are critical for successful RPA signal detections, and should be determined according to the intended use of RPA amplicons. The generation of RPA amplicons are RPA reaction kit dependent. Usage of the TwistAmp® Basic kit (also the Basic RT kits) produces a single amplicon from the forward and reverse primers. Conversely, usage of the TwistAmp® exo kit (also the exo RT kits) and the TwistAmp® fpg kits do not produce a single amplicon, the former is due to the exonuclease present in the reaction mixture digesting most of the amplicons during RPA reaction,<sup>42</sup> and the latter is due to the glycosylase/lyase *E. coli* fpg cleavage generating a non-extensible 3'-phosphate group (also see section 2.3).<sup>46</sup> For the TwistAmp® nfo kit, however, two types of amplicons are generated, due to the DNA polymerase displacement activity to the

probe-primed template: a dual-labelled amplicon emerges as a short product from the probe and one of the primers, whereas a singly-labelled amplicon emerges as a longer product from the forward and reverse primers (Fig. 3C) (note that only the dual-labelled product will generate a positive signal in the test zone of a lateral flow strip detection based on a sandwich assay).<sup>105–108</sup>

Nevertheless, the RPA amplicons are initially associated with proteins and crowding agents, and the resulting DNA-protein-crowding agent complexes prevent direct use of DNA molecules for gel electrophoresis detection.<sup>109,110</sup> This is because these complexes affect the proper migration of the amplicons in gel electrophoresis, leading to a lump of smears on the gel pattern. Several methods have been reported in the literature to process RPA amplicons before gel electrophoresis detection, these include protein denaturation by heating (at 65 °C or 95 °C for 10 minutes) and detergent treatment (e.g. sodium dodecyl sulfate, SDS), enzymatic digestion (e.g. proteinase K), protein sedimentation *via* high-speed centrifugation and purification using commercial DNA clean-up kit.<sup>37,109–113</sup> Among these methods, the heating method worked equivalently to the methods by proteinase K digestion or SDS treatment.<sup>109,111</sup> However, heating at 65 °C for 10 minutes showed better result than that of heating at higher temperature (95 °C).<sup>111</sup> SDS treatment (20% in loading buffer) generated brighter and thicker gel bands than the proteinase K digestion method (0.2 mg mL<sup>-1</sup> or 20 mg mL<sup>-1</sup>);<sup>109</sup> heating at 65 °C for 10 minutes generated equivalent brightness gel bands to the ones generated by SDS treatment method (5% or 10% in the loading buffer) in Londono and co-workers' results, however, Kapoor and co-workers showed that the SDS treatment method (5% in the loading buffer) resulted in brighter gel bands than the heating method (65 °C for 10 minutes) but also resulted in a smear-like pattern above the target band.<sup>111,112</sup> In comparison to the heating, proteinase K digestion and SDS treatment methods, usage of the commercial DNA clean-up kit produced only the target band but in a much lower band intensity.<sup>37,109,111</sup> In addition, as an alternative method, centrifugation (3 minutes) to pellet RPA proteins showed equivalent performance to the heating method (65 °C for 10 minutes).<sup>110</sup>

As with lateral flow strip detection, direct usage of RPA amplicons is possible, but it is recommended to dilute the amplicons with the running buffer (e.g. 1/100 dilution) before running on the strip to (1) improve its wicking performance<sup>114</sup> and (2) avoid "ghost band" effects.<sup>45,54,115–117</sup> Notably, Powell and co-workers pointed out that the viscous wicking problem on the lateral flow strip can be mitigated by replacing the high molecular weight PEG (5.5% 35 kDa; see also section 2.1) with the low molecular weight PEG (6.5% 3 kDa) in the RPA reagent formulae.<sup>114</sup> Moreover, Powell and co-workers also developed methodology to alleviate the dilution step for lateral flow strip detection. They found that sometimes the RPA amplicons are being rendered unavailable in the "RPA globule" (the core of nucleic acid amplification which contains localised RPA reagents; Fig. 5A), the formation of which is highly associated





**Fig. 5** Influence of TwistAmp® nfo formulae and reaction mechanism on lateral flow strip detection. (A) The TwistAmp® nfo amplicons tend to be trapped in a RPA globule (a core of nucleic acid amplification that contains localised RPA reagents), and are consequently impeded for binding to the test line of lateral flow strip. (B) The introduction of a dual-labelled probe (two labels are connected *via* short length linkers) allows escape from the RPA globule trap after enzymatic cleavage. The escaped cleaved dual-labelled probes are readily available for the downstream sandwich assay detection. Reprinted and reproduced with permission from ref. 114. Copyright 2017 Powell *et al.* Published by Elsevier Inc.

with the PEG, for binding to the test line of lateral flow strip. However, applying a dual-labelled probe (two labels are connected *via* short length linkers) enabled escape from the “RPA globule” after the enzymatic cleavage, permitting amplicon ready for down-stream sandwich assay detection (Fig. 5B).<sup>114</sup>

## 2.9 Sensitivities and specificities

The sensitivities and specificities of RPA can be evaluated in two categories, namely analytical and clinical (or field). The analytical sensitivity indicates the lowest amount of analyte that an assay can detect (also known as limit of detection); the analytical specificity is the ability of an assay to measure one particular analyte rather than others in a sample.<sup>118</sup> In comparison, the clinical sensitivity is the percentage of correct

detection of positive clinical samples, while the clinical specificity is the percentage of correct detection of negative clinical samples.

From the analytical sensitivity and specificity perspective, RPA is very sensitive and can detect as little as a few molecules (copies) of the analyte, which approaches the analytical sensitivity of PCR (Table 5). Furthermore, ultra-sensitive detection down to even a single copy of the analyte can also be achieved in RPA (Table 4). In most cases, RPA is very specific for distinguishing one species from other non-closely related species, however, the natural function of these enzymes for performing homology directed repair becomes a disadvantage of RPA to discriminate towards closely-related species, especially when these species share high sequence similarity.<sup>69,87,88</sup> Conversely, this indicates that RPA can tolerate to a certain degree of primers or probe mismatches to the target sequence (more details see section 2.6).

Apart from measuring the analytical sensitivity and analytical specificity, many researchers have applied RPA for testing clinical or field samples, and compared the results with a standard method (mostly PCR). From the summary Table 5, the clinical sensitivity of RPA is only half as sensitive as the benchmark method, whereas the clinical specificity of RPA is most of time as specific as the benchmark method. These results indicate that RPA may (in some cases only), mis-detect a positive sample (false negative), but is unlikely to show a false positive. In short, RPA is still at the beginning of undergoing clinical/field test evaluation, but not yet matured to be a routine test in the clinical/field settings.


## 3. Distinctive RPA detection methods

In the proceeding sections, we have discussed how RPA adapts to commonly used PCR detection methods, such as real-time fluorescent detection, gel electrophoresis and lateral flow strip detection. However, a myriad of different detection methods have been coupled with RPA, including flocculation assay, electrochemical, chemiluminescent, silicon microring resonator (SMR)-based photonic and surface-enhanced Raman scattering (SERS) detections. This section describes these distinctive RPA detection methods and discusses their advantages, which have enabled RPA assays to be more efficient and sensitive, yet sometimes simpler and faster.

### 3.1 Flocculation assay detection

Flocculation assay detection is based on a bridging flocculation phenomenon in colloid chemistry described by Ruehrwein and Ward (in 1952),<sup>158</sup> and later explained by La Mer and Healy (in 1960s).<sup>159–161</sup> The basic principle of bridging flocculation involves the use of long polymers to cross-link multiple particles and thus flocculate out of solution at a specific buffer condition (*e.g.* pH and salt concentration; Fig. 6). A RPA reaction in combination with a flocculation assay detection was first demonstrated by Wee and co-workers, where RPA amplicons greater than 100 bp (from a plant patho-





**Fig. 6** RPA in combination with flocculation assay detection. The RPA amplicons are incubated with magnetic beads at low pH buffer condition. Consequently, the precipitated RPA amplicons on the magnetic bead surfaces cross-link multiple other RPA-magnetic bead conjugates, and thus flocculate out of solution, causing a sharp transition between solution phase and flocculate. RPA reactions with no or non-target template do not produce long “DNA polymer segments”, hence no flocculation takes place. Reprinted and reproduced with permission from ref. 163. Copyright 2015 Springer Nature.


gen) that resembled long polymers were precipitated onto a magnetic bead surface (at low buffer pH).<sup>162</sup> The resulted conjugated particles underwent flocculation due to cross-linking of magnetic beads *via* RPA amplicons. The flocculation could only be triggered with amplified nucleic acids of lengths above 100 nucleotides, which is much longer than standard RPA primers; RPA reaction with no or non-target template did not produce such long “DNA polymer segments” and thus incurred no flocculation.<sup>162</sup> Following from this first application, such RPA-flocculation assays were further applied to detect gene-specific DNA methylation,<sup>163</sup> *Mycobacterium tuberculosis*<sup>96</sup> and prostate cancer biomarkers (TMPRSS2:ERG).<sup>164</sup> Analytical sensitivity of these detections were 10% methylation (from 5 ng of starting material),<sup>163</sup> 10 bacteria colony forming unit (CFU)<sup>96</sup> and 10<sup>5</sup> copies of TMPRSS2:ERG RNA (equivalent to a single cell),<sup>164</sup> respectively. In addition, the detection of TMPRSS2:ERG biomarker underwent clinical sample test, and achieved 70% clinical sensitivity and 100% clinical specificity in comparison to the standard method reverse transcription-PCR.<sup>164</sup>

The flocculation assay detection is a good alternative to the commonly used end-point detection methods (*e.g.* lateral flow strip detection) for quick qualitative detection of RPA amplicons. The total detection time is within ten minutes and only requires a minimum amount of RPA amplicons (10% of the reaction volume). Such detection method does not involve any DNA labelling or modifications during RPA reaction, and it also does not require equipment to confirm the RPA amplicons. The detection is a sharp transition between solution

phase and flocculate, and is therefore better as naked-eye visualisation in comparison to other colourimetric visualisation detections.

### 3.2 Electrochemical detection

Another alternative detection strategy for RPA is electrochemical detection, which employs electrochemically active compounds to produce a signal in relation to the amplified nucleic acids. Most electrochemical approaches for RPA detection measure amperometric signals from RPA-enzyme-linked immunosorbent (ELISA) assay or RPA-enzymatic assay (more details please refer to literature<sup>37,38,43,104</sup>) due to the electrochemically active property of 3,3',5,5'-tetramethylbenzidine (TMB) (Fig. 7).<sup>68,101,102,165–167</sup> Results suggest that electrochemical detection could be up to 10<sup>5</sup>-fold more sensitive than optical detection (by ELISA).<sup>166</sup> Alternatively, Ng *et al.*<sup>103</sup> and Lau *et al.*<sup>100</sup> have applied gold nanoparticles as signal transducers for RPA amplicons detection. The gold nanoparticles can selectively bind to the RPA amplicons *via* specific conjugation, and transfers concentration of RPA amplicons into a measurable electrochemical signal. Again, such electrochemical detection exhibited high analytical sensitivity; Ng *et al.* was able to detect as low as 1 CFU of *Mycobacterium tuberculosis* bacilli DNA, while Lau *et al.* could detect down to 214 pM of *Pseudomonas syringae* (pathogenic bacteria for crops) DNA, which is 100 times more sensitive than RPA-GE detection. Recently, Tsaloglou *et al.*<sup>168</sup> applied [Ru(NH<sub>3</sub>)<sub>6</sub>]<sup>3+</sup> as an electroactive mediator for RPA-electrochemical detection. The [Ru(NH<sub>3</sub>)<sub>6</sub>]<sup>3+</sup> can bind to the double-stranded DNA analogously



**Fig. 7** RPA in combination with electrochemical detection. The example demonstrates electrochemical detection from a RPA-enzymatic assay. The RPA-enzymatic assay is performed in an asymmetric manner, where one of the RPA primers is pre-immobilised on the solid surface, and another RPA primer, together with the DNA template and RPA reagents are free in the solution. After the RPA reaction, streptavidin-conjugated horseradish peroxidase is added, and followed by addition of electrochemically active 3,3',5,5'-tetramethylbenzidine (TMB). The generated electrochemical signal can be detected on a screen printed carbon electrode.<sup>103</sup>



to the intercalating fluorescent dye SYBR Green I, consequently causing a drop in the diffusion-controlled current as more double-stranded DNAs are synthesised during RPA. This ruthenium compound-based electrochemical detection achieved  $11 \text{ CFU mL}^{-1}$  of *Mycobacterium tuberculosis* analytical sensitivity, which is even more sensitive than the GeneXpert MTB/RIF (Cepheid Inc.) detection (a World Health Organisation recommended tuberculosis diagnostic system that employs PCR real-time fluorescent detection;  $131 \text{ CFU mL}^{-1}$ ).

It is obvious that the RPA-electrochemical detection is advantageous for high analytical sensitivity. In addition, RPA-electrochemical detection is fast, low cost and field amenable, as it can be implemented easily with small components manufactured by inexpensive materials (e.g. screen printed carbon electrodes) with signal measured using a portable device (e.g.  $\mu\text{STAT 400}$  bipotentiostat/galvanostat).<sup>101</sup>

### 3.3 Chemiluminescent detection

As an alternative to the fluorescent probe-based detection that requires a light source, RPA reactions can also be detected *via* chemiluminescence. The chemiluminescent detection converts chemical energy into the emission of visible light (luminescence) as the result of an oxidation or hydrolysis reaction.<sup>169</sup> Seidel's research group has been applying RPA coupled with chemiluminescent detection of water-borne microbes on flow-based microarrays.<sup>170,171</sup> Their chemiluminescent detection employs conversion of energy from oxidation between luminol and peroxide catalysed by horseradish peroxidase to give off luminescent signals detected by a charge-coupled device (CCD) camera (Fig. 8).<sup>170,171</sup> Seidel and co-workers first demonstrated a triplex detection of Human adenovirus 41 (HAdV 41), Phi X 174 (a virus) and the bacterium *Enterococcus faecalis* on the chemiluminescent flow-based




Fig. 8 RPA in combination with chemiluminescent detection. The example demonstrates chemiluminescent detection using luminol and peroxide catalysed by horseradish peroxidase on flow-based microarray. The luminescent signal is detected by the CCD camera.<sup>170</sup>


microarray, and achieved the limit of detections of 35 genomic units (GU)  $\mu\text{L}^{-1}$ ,  $1 \text{ GU } \mu\text{L}^{-1}$  and  $5 \times 10^3 \text{ GU } \mu\text{L}^{-1}$ , respectively.<sup>170</sup> The limit of detection of HAdV 41 was in the same range as the TaqMan-qPCR result reported by Heim *et al.* ( $15 \text{ GU } \mu\text{L}^{-1}$ );<sup>172</sup> the limit of detection of *Enterococcus faecalis* was one order of magnitude lower than the reported RPA-electrochemical detection (of a *Francisella tularensis*,  $2 \times 10^4 \text{ GU } \mu\text{L}^{-1}$ ) by Del Rio *et al.*<sup>166</sup> Seidel and co-workers' second demonstration was a duplex detection of *Legionella* spp. and *Legionella pneumophila*, and they achieved the limit of detection of  $87 \text{ GU } \mu\text{L}^{-1}$  and  $26 \text{ GU } \mu\text{L}^{-1}$ , respectively.<sup>171</sup> The *Legionella* spp. could be quantified over four log-steps while the *Legionella pneumophila* could be quantified over five log-steps.<sup>171</sup> In short, the chemiluminescent detection is highly sensitive, having long and stable dynamic range, and is a good candidate for coupling with portable detection device (e.g. a smart phone) in comparison to the fluorescent probe-based detection.

### 3.4 Silicon microring resonator (SMR)-based photonic detection

Detection of RPA reactions can also be performed using silicon microring resonator (SMR)-based photonic detection, which involves performing nucleic acid amplification in an asymmetric manner (pre-immobilised on one of the primers on the SMR, and all the other oligonucleotides and reagents are free in the solution, see also section 4.2) in the evanescent field of a resonator waveguide.<sup>173–175</sup> The binding of nucleic acids to pre-immobilised primers induces changes in the refractive index proximal to the waveguide surface. As the nucleic acid amplification progresses, the wavelength shift due to binding can be monitored in real-time on the SMR (Fig. 9). The SMR-based photonic detection is an alternative detection method for fluorophore-based real-time detection, yet is label-free and much more sensitive. Shin *et al.*<sup>130</sup> achieved the limit of detection for a  $10^{-4}$ -fold diluted sample for *Mycobacterium tuberculosis* detection using real-time PCR, while they could detect down to a  $10^{-6}$ -fold diluted sample when using RPA-SMR detection. Sabaté del Río *et al.*<sup>176</sup> demonstrated that RPA-SMR ( $2 \text{ fg } \mu\text{L}^{-1}$ ) was 1000 times more sensitive than the real-time PCR ( $5 \text{ pg } \mu\text{L}^{-1}$ ) for the detection of *Francisella tularensis*. Jin *et al.*<sup>151</sup> showed that real-time PCR could only detect greater than 30% of the mutant allele in wild-type *KRAS* (a mutant gene in colorectal cancer) populations, while the RPA-SMR detection could detect 1% to 100% of the mutant allele. Since several silicon microrings can be accommodated on the resonator surface, a multiplexed RPA assay is achievable simultaneously on multiple microrings in parallel (also see section 4.2). Liu *et al.*<sup>113</sup> demonstrated a duplex detection of *IS6110* and *IS1081* insertion sequences of *Mycobacterium bovis* Bulgarian BCG using RPA-SMR assay, and achieved 3.2 and 12 genomic DNA copies per reaction analytical sensitivity respectively. Dao *et al.*<sup>177</sup> also demonstrated a duplex RPA-SMR assay for the detection of *Salmonella Typhimurium* and *Brucella ovis*, and they could identify 50 CFU (in 10 mL urine) and 100 CFU (in 10 mL urine) respectively. In comparison to the








**Fig. 9** RPA in combination with silicon microring resonator (SMR)-based photonic detection. An asymmetric RPA reaction is performed on the SMR, where one of the RPA primers is pre-immobilised on the SMR, and another RPA primer, DNA template together with RPA reagents are free in the solution. The binding of DNAs to the pre-immobilised primers induces changes in the refractive index proximal to the waveguide surface, and can be monitored in real-time. The signal is detected as a wavelength shift. Reprinted and reproduced with permission from ref. 130. Copyright 2015 Elsevier B.V. All rights reserved.

multiplex fluorophore-based real-time detection, the multiplex SMR-based photonic detection mitigates potential signal interferences due to fluorophore spectrum overlap, as the wavelength shifts are measured individually on each silicon microring.

### 3.5 Surface-enhanced Raman scattering (SERS) detection

The final method to be highlighted for RPA detection is surface-enhanced Raman scattering (SERS). This is the phenomenon of when a laser excites nanoscale roughened metal surfaces (e.g. gold or silver), which resonantly drives surface charges, creating a highly localised (plasmonic) light field. When a molecule is absorbed, or lies close to, the enhanced field at the surface, a large enhancement in the Raman signal can be observed.<sup>178</sup> SERS is a highly sensitive spectroscopic detection technique, which shows narrow and distinct spectral peaks of the detection molecules, and is par-

ticularly prominent for multiple target molecules detection (Fig. 10). Wang *et al.*<sup>179</sup> demonstrated a duplex RPA-SERS assay for the detection of two prostate cancer biomarkers T1E4 and RN7SL1. The peaks assigned to the phosphate backbone ( $913\text{ cm}^{-1}$ ), purines ( $560, 742$  and  $1334\text{ cm}^{-1}$ ) and pyrimidines ( $1632\text{ cm}^{-1}$ ) could readily be observed in the SERS spectral profiles of both T1E4 and RN7SL1 target amplicons. Lau *et al.*<sup>98</sup> demonstrated a triplex RPA-SERS detection of plant pathogens (*Botrytis cinerea*, *Pseudomonas syringae* and *Fusarium oxysporum*); distinct peaks corresponding to the three pathogens (due to the labelled Raman reporters) could be clearly displayed on the spectrum. Their results also showed that the RPA-SERS detection ( $2.3$  DNA copies) was 100 and 10 000 times more sensitive than RPA-Gel electrophoresis (GE) ( $2.32 \times 10^2$  DNA copies) and PCR-GE ( $2.3 \times 10^4$  DNA copies) detections, respectively. Koo *et al.*,<sup>99</sup> however, has demonstrated the up-to-date highest multiplexity of RPA-SERS assay, a penta-plex



**Fig. 10** RPA in combination with surface-enhanced Raman scattering (SERS) detection. The example demonstrates a penta-plex RPA-SERS assay. The RPA amplicons labelled with Raman reporters are absorbed onto metal nanoparticles. When the laser excites these nanoparticles, a large enhancement in the Raman signals can be observed due to surface charge induced plasmonic light field surrounding the nanoparticles. The signal is displayed as narrow and distinct spectral peaks of the Raman reporters, correlating to different target templates. Reprinted and reproduced with permission from ref. 99. Copyright 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.



detection of prostate cancer biomarkers (T1E4, T1E5, PCA3, ARV7 and RN7SL1). Distinct peaks corresponding to each prostate cancer biomarker was well-separated and clearly observed at  $1075\text{ cm}^{-1}$  (T1E4),  $1175\text{ cm}^{-1}$  (T1E5),  $1285\text{ cm}^{-1}$  (PCA3),  $1338\text{ cm}^{-1}$  (ARV7) and  $1380\text{ cm}^{-1}$  (RN7SL1). In comparison to the SMR-based photonic detection, the SERS detection is also a better suited alternative to the fluorescent-based detection, especially for multiplexed detection. The multiplex ability of SMR-based photonic detection is limited by the number of silicon microrings that can be accommodated on the resonator surface, while the multiplex ability of SERS-based detection is limited by the number of Raman reporters (typically labelled to the target molecules) that produce sharp and unique peaks in the SERS detection.

## 4. Hot spots for RPA development

As demonstrated in the proceeding sections, RPA is a fast developing nucleic acid amplification technique with a growing number of applications and detection systems. In this section, we consider some of the upcoming “hot spots” for RPA development, and discuss their progress and limitations. In particular, we discuss critical advancements in moving RPA into an accurate quantitative technique through the use of digital RPA, as well as increasing the detection capacity through multiplexing. We also outline progress in realising the ability of RPA to break through the bounds of the laboratory for true field implementation, either through mobile laboratory setups (such as the “RPA in a suitcase”), microfluidic integration, or simple single-step RPA procedures.

### 4.1 Quantitative RPA – digital RPA

One of the most important developments of RPA is to quantify nucleic acid amplification, as quantitative nucleic acid amplification can be informative of gene expression levels, enabling better understanding of biological mechanisms, such as gene regulation during replication or pharmacological treatments, or distinguishing symptomatic from asymptomatic infection. However, unlike the classical real-time PCR (or quantitative PCR), real-time RPA is not considered to be robust for nucleic acid quantification. This is because the RPA reaction employs a chemical start (by adding the magnesium acetate) rather than a thermal start (by increasing reaction temperature to  $95\text{ }^{\circ}\text{C}$ ), thus the reaction starting point cannot be precisely controlled. In addition, PCR is synchronised during each thermal cycle, as the annealing occurs only at low temperature, while there is no such synchronisation in RPA, as the annealing takes place all the time at the optimal reaction temperature range. Because of these reasons, RPA generates non-linear calibration curves for quantification.


Nevertheless, the quantification of nucleic acids can be achieved using digital RPA that alleviates calibration curves by the ability of absolute quantification. Digital RPA involves fractionating a nucleic acid sample into thousands to hundred thousands of micro- to pico-litre volume compartments.

Nucleic acid amplification subsequently occurs in each individual compartment. The amplification is usually detected *via* fluorescent probe, and compartments that encase nucleic acid from the sample will give rise to fluorescent signals. At the end of amplification, counting the positive and negative droplets gives precise, absolute quantification of the initial amount of nucleic acid template based on Poisson statistics (the targets end up in partitions independently and with a fixed rate). The published digital RPA reactions can be based on pre-fabricated partition and droplet partition of nucleic acid sample (Fig. 11).

The pre-fabricated partition employs a large amount of “mini-cavities” – wells that can hold a defined volume, which allows massively parallel nucleic acid amplifications. One demonstration of such pre-fabricated partition-based digital RPA is the slipchip.<sup>180,181</sup> The slipchip contains two plates (top and bottom) containing wells and ducts which are pre-loaded with RPA reaction reagents respectively. The RPA reaction is initiated only when the top and bottom plates are aligned in a specific configuration by slipping. Tsaloglou *et al.*<sup>181</sup> demonstrated a slipchip which allowed 8 parallel RPA reactions (each of the eight reactions comprises 500 nL of volume) for the detection of *Clostridium difficile*, and achieved a limit of detection of 1000 DNA copies. Shen *et al.*<sup>180</sup> also demonstrated a slipchip that allowed 1550 parallel RPA reactions (each with 9 nL of volume) for methicillin-resistant *Staphylococcus aureus* (MRSA) detection, and achieved a limit of detection of 300 copies per mL of genomic DNA (Fig. 11A(i)). The other demonstration is on a “microcliff” structured microchip (Fig. 11A(ii)).<sup>182,183</sup> Unlike the slipchip, the sample (nucleic acid and RPA reagents) delivery in this microchip is *via* passive polydimethylsiloxane (PDMS) degas pumping that alleviates external pumps and power source. RPA incubation starts once the sample is delivered into the wells. The “microcliff” structured microchip demonstrated by Yeh *et al.*<sup>182,183</sup> encased 200 to 1500 wells (30–100 nL per well), which allowed detection of  $10\text{--}10^5$  copies per  $\mu\text{L}$  of MRSA DNA. Another demonstration of pre-fabricated partition-based digital RPA is on a pico-liter well array (PWA) chip (27 000 wells, with each well of 314 picolitres, in a  $6\text{ cm}^2$  area; Fig. 11A(iii)).<sup>184</sup> In this chip, the sample was evenly distributed into the wells using a scraping blade. The chip was sealed with oil to prevent evaporation before RPA incubation. The PWA chip could quantify serial dilutions of *Listeria monocytogenes* genomic DNA from  $9 \times 10^{-1}$  to  $4 \times 10^{-3}$  copies per well with an average error of less than 11% ( $n = 15$ ).<sup>184</sup>

The digital RPA by droplet partitions is based on water-in-oil emulsion and is generated by dispersing liquid within an oil phase.<sup>185,186</sup> In this case, each generated droplet acts as an individual micro-reactor, which contains all the reagents for a miniaturised RPA reaction (in the volume range from nanolitre to pico-litre; Fig. 11B(i)). Schuler *et al.*<sup>185</sup> is the first to demonstrate the RPA reaction in water emulsion-based droplets (also called digital droplet RPA, ddRPA), and they successfully quantified *Listeria monocytogenes* DNA (100, 215, 464 and 1000 copies) that was concordant to the number of copies measured with digital droplet PCR.





**Fig. 11** Digital RPA. (A): Digital RPA reaction based on pre-fabricated compartments. (i): Digital RPA on a slipchip. The slipchip contains top and bottom plates that contain wells and ducts which are pre-loaded with RPA reaction reagents respectively. The RPA reaction is initiated only when the top and bottom plate are brought in contact to each other and slipped to a specific configuration. The wells that encase the target DNA will give rise to an end-point fluorescent signal. Reprinted with permission from ref. 180. Copyright 2011 American Chemical Society. (ii): Pre-fabricated partition-based digital RPA on a "microcliff" structured microchip. RPA reagents and extracted DNA are delivered into the microchip *via* passive polydimethylsiloxane (PDMS) degas pumping. The wells that trap target DNA will give rise to an end-point fluorescent signal. Reprinted and reproduced with permission from ref. 183. Copyright 2017 Yeh *et al.* (iii): Pre-fabricated partition-based digital RPA on a pico-litre well array (PWA) chip. The mixture of RPA reagents and *Listeria monocytogenes* genomic DNA is evenly distributed into the wells (314 pL per well) using a scraping blade. The pico-litre wells that trap target DNA will give rise to an end-point fluorescent signal. Reprinted and reproduced with permission from ref. 184. Copyright 2016 Li *et al.* (B): Digital RPA reaction based on droplet partition. (i) Water-in-oil emulsion-based digital droplet RPA reaction produced by multiple nozzles. Mixture of RPA reagents and *Listeria monocytogenes* DNA is dispersed into continuous oil phase. The droplets that encapsulate the *Listeria monocytogenes* DNA will give rise to an end-point fluorescent signal. Reprinted and reproduced with permission from ref. 185. Copyright 2015 The Royal Society of Chemistry.

In summary, the digital RPA partitionates a RPA reaction into nano- or pico-litre sized cavities to allow absolute quantification of the starting nucleic acid. This provides an opportu-

nity to reduce the quantitative variability associated with real-time fluorescent probe-based quantification, as it does not rely on calibration curves. In addition, the digital RPA quanti-



cation is of significant value when testing samples that only contain negligible quantity (prospectively circulating tumour cells) in the original sample; the nucleic acid amplification from such samples can be overwhelmed in the tube (bulk) reaction, whereas, they become conspicuous in the digital RPA reaction.

#### 4.2 Multiplex RPA

While quantitative RPA is critical to measure the amount of a single genetic marker in a system, multiplex testing is critical for assessing a series of different genetic markers, which can be equally important in gaining an improved understanding of a biological system, or for disease monitoring or detection. Multiplexing is highly preferred from a time and precision of understanding, as it greatly increases the result output per sample input in comparison to the single-plex detection within defined analytical turn-around time. Multiplex RPA reaction has been demonstrated either in a single tube (homogenous) or in a parallel fashion (sometimes refers to heterogeneous). The single-tube multiplex RPA can be performed using single or multiple nucleic acid templates. For the former, Kim *et al.*<sup>122</sup> performed a duplex detection of *Campylobacter* species: *Campylobacter coli* and *Campylobacter jejuni* (detection limits of each: 1 CFU mL<sup>-1</sup> in pure culture and in chicken broth samples without enrichment; 3 log CFU g<sup>-1</sup> in non-enriched egg and chicken meat samples; 1 CFU g<sup>-1</sup> in enriched egg and chicken meat samples), and Wang *et al.*<sup>187</sup> conducted a duplex assay to differentiate wild-type and gE-deleted vaccine pseudorabies (limit of detection of 100 viral DNA copies each). However, the highest level of multiplexing is a triplex assay demonstrated by Piepenburg and co-workers for the detection of MRSA I, II and III genotypes (detection limits are 10 genomic copies each).<sup>6</sup> For single-tube multiplex RPA using multiple different nucleic acid templates, a few duplex and triplex assays have been demonstrated for the detection of bacteria,<sup>126,188,189</sup> parasites,<sup>105</sup> fungus,<sup>98</sup> genetic modified soybeans<sup>21</sup> and prostate cancer biomarkers.<sup>179</sup> In particular, Song and co-workers demonstrated the highest multiplexity *via* a 16-plex assay for pathogen detection by combing RPA reactions with LAMP on a microchip, which was termed a two-stage isothermal amplification (Fig. 12A).<sup>190</sup> In Song's demonstration, a first-stage RPA reaction was applied to simultaneously amplify sixteen different DNA targets in the RPA reactor, while a second-stage LAMP reaction was performed in sixteen branching chambers that stemmed from the RPA reactor to amplify and detect the resultant RPA amplicons in parallel. Each of the branching chambers contained a specific set of primers and probe for amplifying a specific pathogen among a pool of sixteen RPA amplicons from the first stage reaction.<sup>190</sup> The RPA-LAMP assay could detect down to 1 plaque-forming units (PFU) using Zika virus-American strain (mex 2-81, Mexico) as a demonstration (amplifying the DNA template with the present of 16 primer pairs), with a linear correlation between 5 PFU and 500 PFU.<sup>190</sup>


Collectively speaking, the single-tube multiplex RPA reaction saves both reaction space and volume. However, further

increasing multiplexing levels is very challenging. In the case of using a single nucleic acid template, the multiplex capacity is mainly restricted by the capacity to accommodate multiple genes within a certain length of consensus sequence. However, the main restriction becomes the non-specific interactions among multiple oligonucleotides (primers, probes and nucleic acid templates) when using multiple nucleic acid templates. Although Song and co-workers' methodology alleviates such restriction (as long as there were few correct RPA amplicons generated in the first-stage reaction, despite concurrently produced non-specific amplicons, these correct RPA amplicons would be specifically further amplified *via* a second-stage LAMP reaction), their methodology is still limited by the capacity of primer concentrations in the first-stage RPA reaction.

In contrast to single-tube multiplex RPA, performing multiplex RPA in a parallel fashion omits the non-specific interactions among multiple oligonucleotides. This is because (1) each single-plex RPA reaction occurs next to each other but is independent of each other (performed as homogeneous assays) or (2) the RPA reaction is performed in an asymmetrical manner (heterogeneous assay), where one of the RPA primer is pre-immobilised on a matrix while the other RPA primer remains in the solution together with the DNA template (and probe), in this way, only the RPA amplicons will be captured on the matrix for detection.

The in-parallel multiplex RPA that adopts homogeneous assay format can be performed either in solution or on a solid phase. For the former, multiple amplicons from collateral single-plex RPA reactions (in tubes) are combined together and submitted to a subsequent multiplex detection method, exemplified by quantum dot beads-coated microwell detection (duplex),<sup>194</sup> quantum dot-based flow cytometry detection (penta-plex)<sup>195</sup> and SERS detection (penta-plex).<sup>99</sup> For the latter, one demonstration is on the digital video disk (DVD) by Maquieira research group, and the resulting signals can be detected by a DVD player (Fig. 12B).<sup>188,191,194</sup> The other demonstration is on an electrowetting-on-dielectric (EWOD) surface, where the EWOD-based RPA reaction droplets are controlled using electric potential by varying electric energy across the thin dielectric film between the liquid and conducting substrate.<sup>80,192</sup> Kalsi *et al.*<sup>192</sup> demonstrated a triplex EWOD-based RPA reaction in a parallel format for the detection of three antibiotic resistant genes (CTX-M-15, KPC and NDM-1). Each single-plex droplet RPA reaction was independent of other single-plex droplet RPA reactions, and could perform a set of programmed operations including move, merge, split, dispense and mix in an automatic manner (Fig. 12C). The EWOD-based RPA reaction achieved the limit of detections of 1000 DNA copies of each antibiotic resistant gene, which is 100 times less sensitive than the bench-top RPA reactions.<sup>192</sup> Another demonstration is on paper by Magro and co-workers, which they constructed a wax patterned five-layer paper device in three-dimensional (3D) origami configuration (Fig. 12D).<sup>193</sup> Freeze-dried RPA reaction reagents were pre-stored on multiple individual wax patterned areas. Once the liquid sample





**Fig. 12** Multiplex RPA. (A): Example of single-tube multiplex RPA via a two-stage isothermal amplification (RPA in combination with LAMP). Sixteen different DNA targets are amplified using RPA in the RPA reactor at the first stage, followed by metering the resulting mixture of RPA amplicons into sixteen branching LAMP reactors that have been pre-stored with set of LAMP primers and probe for a specific pathogen detection respectively. If the DNA targets are present in the sample and are successfully amplified by RPA, the branching LAMP reactors will produce fluorescent signals. Reprinted with permission from ref. 190. Copyright AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, INC. (B): Example of in-parallel multiplex RPA that adopts homogeneous assay format on a DVD. RPA reaction mixtures are pipetted onto a DVD as a microarray. Reprinted with permission from ref. 191. Copyright 2014 Elsevier Ltd. All rights reserved. (C) Example of in-parallel multiplex RPA that adopts homogeneous assay format on electrowetting-on-dielectric (EWOD) surface. The example demonstrates a triplex RPA reaction (each sample with 3 replicates and duplicates negative control) for the detection of anti-microbial resistance genes in Gram-negative microorganisms. The mixing of different components of RPA reagents can be performed at desired time-points and in a sequential manner, as the RPA reaction droplets can be individually manipulated (dispensing, splitting or mixing) via the phenomenon of EWOD. The RPA reaction droplets that contain the DNA target will give rise to an end-point fluorescent signal. Reprinted and reproduced with permission from ref. 192. Copyright 2017 Kalsi *et al.* (D) Example of in parallel multiplex RPA that adopts homogeneous assay format on a 3D origami paper-based device. Schematic view of the 3D origami paper-based device showing the location of freeze-dried biological components (real-time RPA reagents with three different primers and associated RNA templates) on wax patterned areas (left). Application of three different coloured dyes to display the multiplex RPA detection (right). After supplying the sample, dipping into the water and being folded, the input sample will flow along the defined patterns via capillary force between adjacent paper layers, and finally reach to the desired areas for RPA amplification. Reprinted with permission from ref. 193. Copyright 2017 Springer Nature.

mixture was pipetted onto the sample inlet, the input liquid sample mixture could be distributed via capillary force between adjacent paper layers by folding, and ultimately reached specific areas that contained pre-stored reagents, to initiate RPA reactions.

Unlike the in-parallel multiplex RPA that adopts homogeneous assay format, the demonstrations of the in-parallel

multiplex RPA that adopts heterogeneous assay takes place only on solid surfaces. The majority of such assay performs multiplex RPA in an asymmetric manner on a microarray. Kersting *et al.*<sup>196</sup> performed triplex RPA in a 4 × 6 microarray for the detection of *Salmonella enterica*, *Neisseria gonorrhoeae* and MRSA on the epoxy-silanised glass slides, and achieved detection limits of 10 CFU, 100 CFU and 10 CFU respectively.



Kunze *et al.*<sup>170</sup> conducted triplex RPA in a  $5 \times 5$  microarray for the detection of *Enterococcus faecalis*, Human adenovirus 41 (HADV 41) and Phi X 174 virus on the poly(propylene glycol) diamine (DAPPG) coated glass slides (also see section 3.3), and achieved detection limits of  $35 \text{ GU } \mu\text{L}^{-1}$ ,  $1 \text{ GU } \mu\text{L}^{-1}$  and  $5 \times 10^3 \text{ GU } \mu\text{L}^{-1}$  respectively. Another demonstration of such an assay is the performance of multiple single-plex RPA reactions on multiple silicon microrings fitted on a resonator surface, demonstrated by Liu *et al.*<sup>113</sup> and Dao *et al.*<sup>177</sup> (more details refer to section 3.4).


Taken together, the multiplex RPA in a parallel fashion has a much higher assay throughput, circumvents cross-reaction (among oligonucleotides) issues, and possesses higher multiplex capacity compared to the single-tube multiplex RPA. However, its degree of multiplexing is limited by (1) the number of available unique labels conjugated to multiple nucleic acid templates which permit distinctive detection; (2) the size of the reaction surface; and (3) EWOD-based RPA reaction is also limited by the minimum volume of the droplet that permits an effective reaction.

### 4.3 RPA in a suitcase for mobile laboratory

The ultimate purpose of isothermal amplification such as RPA is to take the nucleic acid testing away from the centralised lab to the field or resource-limited settings. Abd El Wahed and co-workers turned this thought into reality by miniaturising the RPA diagnostic into a standard suitcase ( $56 \text{ cm} \times 45.5 \text{ cm} \times 26.5 \text{ cm}$  by size), dubbed diagnostics-in-a-suitcase (Dias; costs around 5000 Euro; Fig. 13A).<sup>197</sup> The Dias contained all the reagents and equipment necessary for the real-time RPA assay to detect the emerging avian influenza A (H7N9) virus at the

site of an outbreak. The reagents and the equipment were fixed in the foam at the base of the suitcase which acted as a shock absorber during transport; a solar panel and a power pack provided the power support; and the storage box was refillable whenever needed.<sup>197</sup> The RPA-Dias detection of influenza A (H7N9) was successful, and achieved detection limits of 10 and 100 RNA copies for the detection of H gene and N gene, respectively.

This highly promising demonstration of the first RPA-Dias inspired Abd El Wahed and co-workers to perform further testing. They carried the Dias (a total weight of 23 kilograms including the aluminium case) to the field of both of Kedougou (Senegal) and Bangkok (Thailand), and set up a mobile laboratory for the real-time RPA detection of dengue virus (1–4 serotypes).<sup>131</sup> The mobile lab was organised into 4 sites, including the RNA extraction, master mix, sample mix and detection (using a tubescanner, TwistDx, Cambridge, UK) in close proximity (Fig. 13B).<sup>131</sup> All the reagents were cold-chain independent; the power was supplied either from a motor vehicle battery (*via* inverter) or from the solar panel. The real-time RPA assay performed successfully in such an open-air environment and observed no influence of dust on the assay quality. The clinical sensitivities and specificities tested in Kedougou (Senegal) and Bangkok (Thailand) were 98% and 100% and 72% and 100%, respectively.<sup>131</sup> Later, Abd El Wahed and co-workers also carried the Dias to the local hospitals in Matoto (Guinea)<sup>134</sup> and Mymensingh (Bangladesh)<sup>121</sup> for the on-site detection of Ebola virus and *Leishmania donovani*, respectively. The real-time RPA Ebola assay was able to correctly include positives (91% of clinical sensitivity) and exclude negatives (100% of clinical specificity);<sup>134</sup> while the



**Fig. 13** Mobile RPA assay. (A): RPA in-a-suitcase. The standard suitcase ( $56 \text{ cm} \times 45.5 \text{ cm} \times 26.5 \text{ cm}$  by size) contains all equipment and reagents for performing the real-time RPA assay. The equipment and reagents are imbedded into the foam or fixed for stable portability. Reprinted with permission from ref. 197. Copyright 2015 Abd El Wahed *et al.* Published by Elsevier B.V. (B): A mobile laboratory set up from the "RPA in-a-suitcase". The mobile lab is arranged into 4 sites in close proximity, including the RNA extraction, master mix, sample mix and detection. The RNA extraction area encompasses magnetic separator stand, vortex, rotator, 1.5–2 mL Eppendorf tube rack, automatic 100–1000  $\mu\text{L}$  micropipette, micropipette tips, digital timer, 1.5 mL disposable plastic Eppendorf tubes and a waste container with autoclavable plastic bags. Both the master mix and sample mix areas contain vortex, minicentrifuge, automatic 1–10 and 10–100  $\mu\text{L}$  micropipettes, micropipette tips, scissor and 0.2 mL tubes rack. The detection was done using the tubescanner (Twista device, TwistDx, Cambridge, UK). Reprinted with permission from ref. 131. Copyright 2015 Abd El Wahed *et al.*



real-time RPA *Leishmania donovani* assay achieved 100% clinical sensitivity and 100% clinical specificity.<sup>121</sup> The demonstration of RPA-Dias brings the rapid nucleic acid testing to the site of need, in particular benefiting the places with poor laboratory infrastructure. With its continuous development, there is no doubt that the RPA-Dias will become pervasive within five years.


#### 4.4 Microfluidic integration of RPA assays

Apart from multiplex RPA reactions and mobile RPA reactions that provide increasing diagnostic efficiency and portability respectively, a growing attention has been focused on developing RPA assays that encompasses both of the two merits. The solution is to integrate RPA amplification with other chemical processes on a miniaturised device using microfluidics. The major chemical processes to combine with RPA amplification for an intact diagnosis are sample preparation, amplification and signal detection. There have been a few examples of integrating RPA amplification with signal detection, however, only few demonstrations have been performed integrating all of the three processes. Branavan *et al.*<sup>198</sup> developed a microfluidics that integrated RPA amplification and fluorescent signal detection for the detection of sexually transmitted infections; Renner *et al.*<sup>47</sup> developed a degas-actuated microfluidics that integrated multiplex RPA amplification and fluorescent signal detection for the detection of ESKAPE (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* spp.) bacterial pathogens; and Hu *et al.*<sup>199</sup> developed thin film transistor-based microfluidics that integrated RPA amplification and electronic signal detection for the detection of anti-microbial resistance genes. We note that all these three examples require the input of manually pre-mixed RPA reaction reagents. For fully integrated assays, one demonstration is the self-powered integrated microfluidic by Yeh *et al.*<sup>183</sup> The self-powered integrated microfluidic integrated sample preparation (plasma separation from blood cells), digital RPA amplification (pre-partition-based) and detection (fluorescent-probe based) in an automatic manner *via* a built-in vacuum battery system (that frees the chip from external pumps sources for pumping).<sup>183</sup> The self-powered integrated microfluidic was able to detect  $2 \times 10^5$  copies per  $\mu\text{L}$  of HIV-1 RNA spiked in human blood within 18 minutes, and was able to quantitatively detect 10 to  $10^5$  copies per  $\mu\text{L}$  of MRSA DNA in water or directly from spiked human whole blood.<sup>183</sup> Another demonstration of fully integrated assays is the application of centrifugal microfluidics that perform all the required procedure for RPA reaction in an automatic manner governing by centrifugal forces. Zengerle's research group was the first one to demonstrate such performance. They developed a foil disc (Fig. 14A) that performs metering of the RPA rehydration buffer to re-suspend RPA reaction pellet, and subsequently aliquot the resulting mixture into five parallel reaction chambers that were pre-stored with oligonucleotides (primers, probe and DNA template).<sup>200</sup> The foil disc was fitted onto a modified Rotor-Gene 2000, which executed centrifugation to manipulate the liquid movement between

different chambers on the foil disc and real-time fluorescent signal detection. Followed up this demonstration, they developed another foil disc that integrated sample preparation (DNA extraction from blood plasma), nucleic acid amplification and fluorescent detection of *Bacillus anthracis* and *Francisella tularensis*.<sup>201</sup> And this time, they tailor-made a portable LabDisk Player (approximately  $18 \times 28 \times 15 \text{ cm}^3$  and 2 kilograms by weight) which could process the integrated chemical processes on the foil disc in an automatic manner. The fully integrated microfluidic RPA assay detected  $6 \times 10^4$  genome equivalents of *Bacillus anthracis* and  $6 \times 10^6$  genome equivalents of *Francisella tularensis* in less than 45 minutes.<sup>201</sup> Their centrifugal microfluidics is the first true example of fully integrated RPA assay device, with the entire procedure from DNA extraction through to detection, in a fully automated fashion. Later, Kim *et al.*<sup>202</sup> also developed a centrifugal microfluidics that integrated sample lysis, RPA amplification, metering, dilution and lateral flow strip detection of food-borne pathogen (*Salmonella enteritidis*; Fig. 14B). The centrifugal microfluidics was fitted onto a computer-controlled unit that included a spinning motor, a laser for sample lysis and a local heating apparatus to support RPA assay procedure. Their demonstration achieved the limit of detections of  $10 \text{ CFU mL}^{-1}$  and  $100 \text{ CFU mL}^{-1}$  in phosphate-buffered saline (PBS) and milk respectively with a total analysis time of 30 minutes.<sup>202</sup>

The foil-based microfluidics described above are a compact and affordable platform for performing integrated RPA assays, but they require complicated and expensive design and fabrication. Nonetheless, paper-based microfluidics can be an alternative for performing integrated RPA assays, as they can also conduct many of the functions of the foil-based microfluidics. Cordray and Richards-Kortum<sup>106</sup> developed a paper-based microfluidics that integrated RPA amplification, dilution and lateral flow strip detection. All the reagents for this three processes were pre-stored in different paper pads, and were mixed with each other sequentially by pulling the sliders (Fig. 14C).<sup>106</sup> Their paper-based integrated RPA assay could detect as few as 50 synthetic *Plasmodium* DNA copies, which was equivalent to the analytical sensitivity of the bench-top RPA-GE assay. In comparison, Magro *et al.*<sup>193</sup> developed a 3D origami paper-based device that integrated multiplex RPA amplification and fluorescent signal detection (refer to section 4.2). The pre-stored reagents and oligonucleotides in different wax-patterned areas were rehydrated once the device is folded and dipped into water. Although the integration of RPA amplification and signal detection showed successful paper-based microfluidics, it required human intervention to complete the integrated RPA assay, as opposed to a fully integrated RPA assay on foil-based microfluidics. Moreover, it is very challenging to integrate sample preparation with RPA amplification and signal detection on paper-based microfluidics, not to mention in an automated execution. The reason is that it is very difficult to manipulate liquid movement on paper merely *via* capillary force, which is a weak force, and thus results in a slow moving process (despite of the liquid has a high wettability and the matrix is very hydrophilic and porous).





**Fig. 14** Integrated RPA assays on microfluidics. (A): Centrifugal microfluidics that integrates RPA reagents metering, mixing and aliquoting, amplification and fluorescent signal detection. Photograph of a foil disc assembled with RPA reaction reagents (liquid and lyophilisate reagents) featuring 6 fluidic structures (top), each capable of processing 5 geometrically multiplexed assays. Detailed fluidic structure for one unit is denoted; the buffer is replaced by red ink for demonstration purposes (bottom left). Elucidation of automated RPA assay on a centrifugal microfluidic (bottom right); fluids movement between chamber to chamber are manipulated *via* centrifugal force. (i) Inside the glass capillary contains the RPA liquid reagents, including DNA template, primers, probe, rehydration buffer, magnesium acetate, while the lyophilisate chamber contains the lyophilised pellet; (ii) the RPA liquid reagents is spun into the lyophilisate chamber after the glass capillary is crushed; (iii) the siphon allows valving between the lyophilisate chamber and the aliquoting structure; (iv) the 50  $\mu\text{L}$  RPA liquid reagents volume is split into  $5 \times 10 \mu\text{L}$  aliquots; and (v) the fluid fills the reaction chambers *via* a centrifugal pneumatic valve. Reprinted with permission from ref. 200. Copyright 2010 Royal Society of Chemistry. (B): Centrifugal microfluidics that integrated sample lysis, RPA amplification, metering, dilution and lateral flow strip detection. Reprinted with permission from ref. 202. Copyright 2014 American Chemical Society. (C): Paper-based microfluidics that integrates RPA amplification, dilution and lateral flow strip detection. (i) Layout and components of the device; (ii) operations of the device: (a) sample slider at position 1, mixing RPA reagents and target to initiate the amplification (30 minutes of incubation); (b) after amplification, the sample slider pulled down to position 2, in contact with dry dilution pads to absorb RPA buffer (10 minutes of duration); (c) the sample slider pulled down to position 3, in contact with wet dilution pads, for dilution with TBST buffer (10 minutes of duration); and (d) the sample slider pulled down to position 4 into contact with the lateral flow strip, and the running buffer slider is pulled down to activate the lateral flow detection (5 minutes of duration). Reprinted with permission from ref. 106. Copyright 2015 Cordray and Richards-Kortum.

Overall, developing a microfluidically integrated RPA assay is a transition towards the realisation of fully automated sample-in-answer-out RPA assay to increase the diagnostic efficiency and portability. Nevertheless, the sample preparation step is the bottleneck to achieve this ultimate goal. In particular, some samples (*e.g.* blood) require multiple processing steps before the extracted nucleic acids are ready for the subsequent amplification and detection. Zengerle's research group and Kim and colleagues' work by employing multiple

sample preparation chambers together with the amplification chamber (and detection chamber) on a single foil-based microfluidics, demonstrates one feasible way, albeit with challenging and costly microfluidics design and fabrication.

#### 4.5 One-step RPA assays

A simple and feasible way to facilitate full automation of the RPA assay without introducing multiple sample preparation chambers is to perform a one-step RPA assay, or in other





words, to perform RPA amplification directly from the crude sample (in the same tube). RPA has been able to amplify nucleic acids directly from crude samples, such as plant tissue extract,<sup>111,203</sup> crude sap,<sup>79,112</sup> soil and water samples,<sup>71</sup> food samples (eggs and chicken meat)<sup>119</sup> and vaginal swab lysate.<sup>137</sup>

Nevertheless, Choi and co-workers were the first to demonstrate a fully integrated RPA assay on foil-based microfluidics that was facilitated by the one-step assay approach. Choi *et al.* employed direct PCR buffer in RPA reaction for the detection of food poisoning bacteria (*Salmonella enterica*, *Escherichia coli* O157:H7 or *Vibrio parahaemolyticus*).<sup>204,205</sup> The direct PCR buffer was able to lyse the bacterial cells, inactivate amplification inhibitors from the lysed sample and was compatible to the RPA reaction system.<sup>204</sup> The entire assay completed within 30 minutes, which was much shorter than the time required for a non-sample preparation integrated microfluidic or a sample preparation integrated microfluidic system (*e.g.* at least 60 minutes). Although the direct RPA assay is a shortcut to assist full automation of foil-based microfluidics, there is no rule of thumb for the direct RPA assay buffer. This is because each sample has different lysis difficulty levels, and the effective lysis buffer may not be compatible with the RPA system and may also have potential impact on fluid movement within the microfluidics. Therefore, it is a trail-and-error process to identify such effective direct RPA buffers.

## 5. Conclusions and future perspectives

The PCR is a revolutionary watershed in nucleic acid test, however, isothermal nucleic acid amplification, as an alternative to PCR, has a lower requirement in heating conditions and performs nucleic acid replication more rapidly. RPA was a comparatively late introduced isothermal amplification method, however, it is one of the fastest developing methods. This is due to its true isothermal properties, simple reaction scheme, fast reaction time and excellent reports of sensitivity and specificity. In this review, we provide comprehensive knowledge of RPA technology: from its reaction components and mechanism, to the design of RPA assay and detection methods. In particular, we summarise many experimental tips from practical implementation, dispose clinical/field performance data and point out focused RPA development, to help researchers make better use of RPA and make contributions to boost its development.

RPA has just passed its first decade of development, and is now stepping into a next stage of evolution. We have considered some critical issues for future development. Firstly, more attention is needed for developing field-amenable sample preparation methods including concentration, extraction and purification, as this would largely facilitate a complete RPA assay for on-site or field application. Secondly, developing portable and fully automated RPA diagnostic devices is of paramount importance not only to further increase the diagnostic efficiency, but more importantly to bring RPA diagnostic

closer to the layperson and people who live in places with poor healthcare infrastructure. Thirdly, RPA can be applied for developing wearable sensors by virtue of its close-to-body reaction temperature. Imagine if people can simply take some samples from their own body (*e.g.* body fluid) and perform a fast RPA assay using their body temperature to detect potential pathogens, this could revolutionise RPA diagnostics to be a self-testing. Fourthly, unlike real-time PCR which is controlled by heat cycle, RPA employs continuous amplification after reaction initiation; it would be beneficial to develop a method or mechanism to precisely control the starting point of each RPA amplification cycle, so as to assist obtaining reliable quantitative RPA results (other than the absolute quantification by digital RPA). Fifthly, the current market share of RPA (7.08%) is far less than that of PCR, and is less in comparison to other isothermal nucleic acid amplification methods (*e.g.* SDA and LAMP). To boost its market share, more studies in comparative clinical validations between RPA and existing PCR assays can be performed. In addition, practical websites or software should be developed to ease and streamline the RPA primers and probe design, and screen for optimal oligonucleotide pairs for the reaction. Rationally speaking, RPA may not replace the status of PCR in years to come, but it can be a versatile complement of PCR. At this time point, RPA technology is maturing for application in the clinic, however, it is still at a transition period towards on-site or field application. With its continuous fast development, we foresee that RPA technology will ultimately become robust mobile and point-of-need applications in the future.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was funded by Alexander von Humboldt Fellowship. We also acknowledge the financial support from the Baden-Württemberg Ministry for Economy, Labour and Housing (project "IDAK" AZ 7-4332.62-HSG/69) and the Queensland Government, Department of Science, Information Technology, Innovation and the Arts (DSITIA, Australia).

## References

- 1 K. Mullis, F. Faloona, S. Scharf, R. Saiki, G. Horn and H. Erlich, *Cold Spring Harbor Symp. Quant. Biol.*, 1986, **51**(Part 1), 263–273.
- 2 J. Li and J. Macdonald, *Biosens. Bioelectron.*, 2014, **64C**, 196–211.
- 3 P. Craw and W. Balachandran, *Lab Chip*, 2012, **12**, 2469–2486.
- 4 P. Gill and A. Ghaemi, *Nucleosides, Nucleotides Nucleic Acids*, 2008, **27**, 224–243.



- 5 Y. Zhao, F. Chen, Q. Li, L. Wang and C. Fan, *Chem. Rev.*, 2015, **115**, 12491–12545.
- 6 O. Piepenburg, C. H. Williams, D. L. Stemple and N. A. Armes, *PLoS Biol.*, 2006, **4**, e204.
- 7 Isothermal nucleic acid amplification technology (INAAT) market analysis by product, by technology (NASBA, HDA, LAMP, SDA, SPIA, NEAR, TMA, RCA, RPA, SMAP2), and segment forecasts, 2018–2025, Report GVR-1-68038-588-5, Grand View Research, 2017.
- 8 H. Zaghoul and M. El-Shahat, *World J. Hepatol.*, 2014, **6**, 916–922.
- 9 M. D. Moore and L.-A. Jaykus, *Future Virol.*, 2017, **12**, 421–429.
- 10 A. James and J. Macdonald, *Expert Rev. Mol. Diagn.*, 2015, **15**, 1475–1489.
- 11 R. K. Daher, G. Stewart, M. Boissinot and M. G. Bergeron, *Clin. Chem.*, 2016, **62**, 947–958.
- 12 I. M. Lobato and C. K. O'Sullivan, *TrAC, Trends Anal. Chem.*, 2018, **98**, 19–35.
- 13 J. Griffith and T. Formosa, *J. Biol. Chem.*, 1985, **260**, 4484–4491.
- 14 M. Bianchi, B. Riboli and G. Magni, *EMBO J.*, 1985, **4**, 3025–3030.
- 15 J. M. Boyle and N. Symonds, *Mutat. Res.*, 1969, **8**, 431–439.
- 16 Y. Shamoo, A. M. Friedman, M. R. Parsons, W. H. Konigsberg and T. A. Steitz, *Nature*, 1995, **376**, 362–366.
- 17 B. M. Alberts and L. Frey, *Nature*, 1970, **227**, 1313–1318.
- 18 T. Okazaki and A. Kornberg, *J. Biol. Chem.*, 1964, **239**, 259–268.
- 19 M. Euler, Y. Wang, P. Otto, H. Tomaso, R. Escudero, P. Anda, F. T. Hufert and M. Weidmann, *J. Clin. Microbiol.*, 2012, **50**, 2234–2238.
- 20 RPA Assay Design, <https://www.twistdx.co.uk/en/support/rpa-assay-design-2>, (accessed Oct 4th, 2018).
- 21 D. Chandu, S. Paul, M. Parker, Y. Dudin, J. King-Sitzes, T. Perez, D. W. Mittanck, M. Shah, K. C. Glenn and O. Piepenburg, *BioMed. Res. Int.*, 2016, **2016**, 3145921.
- 22 S. B. Zimmerman and B. Harrison, *Proc. Natl. Acad. Sci. U. S. A.*, 1987, **84**, 1871–1875.
- 23 R. J. Ellis, *Trends Biochem. Sci.*, 2001, **26**, 597–604.
- 24 Y. Sasaki, D. Miyoshi and N. Sugimoto, *Biotechnol. J.*, 2006, **1**, 440–446.
- 25 S. Fjelstrup, M. B. Andersen, J. Thomsen, J. Wang, M. Stougaard, F. S. Pedersen, Y.-P. Ho, M. S. Hede and B. R. Knudsen, *Sensors*, 2017, **17**, 1201.
- 26 Creatine kinase, [https://en.wikipedia.org/wiki/Creatine\\_kinase](https://en.wikipedia.org/wiki/Creatine_kinase), (accessed Oct 4, 2018).
- 27 Tris, <https://en.wikipedia.org/wiki/Tris>, (accessed Oct 4th, 2018).
- 28 cambio, Lab Reagents: Smart Buffers and Reagents, <https://www.cambio.co.uk/24/1283/77/products/potassium-acetate/#tab-2>, (accessed July 27th, 2018).
- 29 T. Yonesaki and T. Minagawa, *EMBO J.*, 1985, **4**, 3321–3327.
- 30 L. D. Harris and J. Griffith, *J. Biol. Chem.*, 1987, **262**, 9285–9292.
- 31 TwistDxLtd., TwistAmp® combined instruction manual, [https://www.twistdx.co.uk/docs/default-source/RPA-assay-design/ta01cmanual-combined-manual\\_revo\\_v1-3a.pdf?sfvrsn=6](https://www.twistdx.co.uk/docs/default-source/RPA-assay-design/ta01cmanual-combined-manual_revo_v1-3a.pdf?sfvrsn=6), (accessed Oct 4th, 2018).
- 32 M. M. Cox and I. R. Lehman, *J. Biol. Chem.*, 1982, **257**, 8523–8532.
- 33 L. D. Harris and J. D. Griffith, *J. Mol. Biol.*, 1989, **206**, 19–27.
- 34 T. Yonesaki and T. Minagawa, *J. Biol. Chem.*, 1989, **264**, 7814–7820.
- 35 K. Hashimoto and T. Yonesaki, *J. Biol. Chem.*, 1991, **266**, 4883–4888.
- 36 M. Euler, Y. Wang, O. Nentwich, O. Piepenburg, F. T. Hufert and M. Weidmann, *J. Clin. Virol.*, 2012, **54**, 308–312.
- 37 S. Martorell, S. Palanca, A. Maquieira and L. A. Tortajada-Genaro, *Anal. Biochem.*, 2017, **544**, 49–56.
- 38 M. Jauset-Rubio, J. Sabate Del Rio, T. Mairal, M. Svobodova, M. S. El-Shahawi, A. S. Bashammakh, A. O. Alyoubi and C. K. O'Sullivan, *Anal. Bioanal. Chem.*, 2017, **409**, 143–149.
- 39 M. Jauset-Rubio, M. Svobodova, T. Mairal, C. McNeil, N. Keegan, M. S. El-Shahawi, A. S. Bashammakh, A. O. Alyoubi and C. K. O'Sullivan, *Anal. Chem.*, 2016, **88**, 10701–10709.
- 40 M. Jauset-Rubio, M. Svobodova, T. Mairal, C. McNeil, N. Keegan, A. Saeed, M. N. Abbas, M. S. El-Shahawi, A. S. Bashammakh, A. O. Alyoubi and O. S. CK, *Sci. Rep.*, 2016, **6**, 37732.
- 41 J. Wang, J. Wang, Y. Geng and W. Yuan, *Can. J. Vet. Res.*, 2017, **81**, 308–312.
- 42 TwistAmp® manuals, <https://www.twistdx.co.uk/en/support/manuals/twistamp-manuals>, (accessed Oct 4th, 2018).
- 43 O. Mayboroda, A. Gonzalez Benito, J. Sabate del Rio, M. Svobodova, S. Julich, H. Tomaso, C. K. O'Sullivan and I. Katakis, *Anal. Bioanal. Chem.*, 2016, **408**, 671–676.
- 44 R. Wang, F. Zhang, L. Wang, W. Qian, C. Qian, J. Wu and Y. Ying, *Anal. Chem.*, 2017, **89**, 4413–4418.
- 45 S. L. Fuller, E. A. Savory, A. J. Weisberg, J. Z. Buser, M. I. Gordon, M. L. Putnam and J. H. Chang, *Phytopathology*, 2017, **107**, 1062–1068.
- 46 O. Piepenburg and N. A. Armes, DNA glycosylase/lyase and AP endonuclease substrates, Alere San Diego, Inc., US20110053153 A1, 2011.
- 47 L. D. Renner, J. Zan, L. I. Hu, M. Martinez, P. J. Resto, A. C. Siegel, C. Torres, S. B. Hall, T. R. Slezak, T. H. Nguyen and D. B. Weibel, *Appl. Environ. Microbiol.*, 2017, **83**, e02449–e02416.
- 48 T. A. Hall, BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT, *Nucleic acids symposium series*, 1999, vol. 41, pp. 95–98.
- 49 T. Koressaar and M. Remm, *Bioinformatics*, 2007, **23**, 1289–1291.
- 50 N. R. Markham and M. Zuker, *Methods Mol. Biol.*, 2008, **453**, 3–31.



- 51 M. Zuker, *Nucleic Acids Res.*, 2003, **31**, 3406–3415.
- 52 S. Hoshika, F. Chen, N. A. Leal and S. A. Benner, *Nucleic Acids Symp. Ser.*, 2008, 129–130.
- 53 N. Sharma, S. Hoshika, D. Hutter, K. M. Bradley and S. A. Benner, *ChemBioChem*, 2014, **15**, 2268–2274.
- 54 Y. Yang, X. Qin, W. Zhang, Y. Li and Z. Zhang, *Mol. Cell. Probes*, 2016, **30**, 300–305.
- 55 X. Xia, Y. Yu, L. Hu, M. Weidmann, Y. Pan, S. Yan and Y. Wang, *Arch. Virol.*, 2015, **160**, 987–994.
- 56 TwistDxLtd., TwistDx, <https://www.twistdx.co.uk>, (accessed Oct 4th, 2018).
- 57 L. Lillis, J. Siverson, A. Lee, J. Cantera, M. Parker, O. Piepenburg, D. A. Lehman and D. S. Boyle, *Mol. Cell. Probes*, 2016, **30**, 74–78.
- 58 TwistDxLtd., Custom freeze-drying, <https://www.twistdx.co.uk/en/products/custom-freeze-drying>, (accessed May 3rd, 2018).
- 59 G. Posthuma-Trumpie, J. Wichers, M. Koets, L. J. M. Berendsen and A. Amerongen, *Anal. Bioanal. Chem.*, 2012, **402**, 593–600.
- 60 K. Poulton and B. Webster, *Anal. Biochem.*, 2018, **546**, 65–71.
- 61 Z. A. Crannell, B. Rohrman and R. Richards-Kortum, *PLoS One*, 2014, **9**, e112146.
- 62 S. Kersting, V. Rausch, F. F. Bier and M. von Nickisch-Rosenegk, *Malar. J.*, 2014, **13**, 99.
- 63 L. Lillis, D. Lehman, M. C. Singhal, J. Cantera, J. Singleton, P. Labarre, A. Toyama, O. Piepenburg, M. Parker, R. Wood, J. Overbaugh and D. S. Boyle, *PLoS One*, 2014, **9**, e108189.
- 64 Y. Yang, X. Qin, G. Wang, J. Jin, Y. Shang and Z. Zhang, *Virol. J.*, 2016, **13**, 46.
- 65 K. Sun, W. Xing, X. Yu, W. Fu, Y. Wang, M. Zou, Z. Luo and D. Xu, *Parasites Vectors*, 2016, **9**, 476.
- 66 M. A. Prescott, A. N. Reed, L. Jin and M. K. Pasty, *J. Aquat. Anim. Health*, 2016, **28**, 173–180.
- 67 F. Yin, J. Liu, A. Liu, Y. Li, J. Luo, G. Guan and H. Yin, *Vet. Parasitol.*, 2017, **237**, 125–129.
- 68 J. S. Del Rio, I. M. Lobato, O. Mayboroda, I. Katakis and C. K. O'Sullivan, *Anal. Bioanal. Chem.*, 2017, **409**, 3261–3269.
- 69 Y. Yang, X. Qin, Y. Sun, G. Cong, Y. Li and Z. Zhang, *BioMed. Res. Int.*, 2017, **2017**, 8403642.
- 70 Y. Yang, X. Qin, W. Zhang, Z. Li, S. Zhang, Y. Li and Z. Zhang, *Mol. Cell. Probes*, 2017, **33**, 32–35.
- 71 Y. D. Wu, M. J. Xu, Q. Q. Wang, C. X. Zhou, M. Wang, X. Q. Zhu and D. H. Zhou, *Vet. Parasitol.*, 2017, **243**, 199–203.
- 72 N. Valasevich and B. Schneider, *J. Phytopathol.*, 2017, **165**, 762–770.
- 73 E. Tian, Q. Liu, H. Ye, F. Li and Z. Chao, *Molecules*, 2017, **22**, 2261–2270.
- 74 P. Hou, G. Zhao, H. Wang, C. He, Y. Huan and H. He, *Mol. Cell. Probes*, 2018, **38**, 31–37.
- 75 M. Y. Lai, C. H. Ooi and Y. L. Lau, *Am. J. Trop. Med. Hyg.*, 2018, **98**, 700–703.
- 76 Z. Guimin, W. Hongmei, H. Peili, H. Chengqiang and H. Hongbin, *J. Vet. Sci.*, 2017, **19**, 242–250.
- 77 G. Zhao, H. Wang, P. Hou, C. He and H. He, *J. Vet. Sci.*, 2018, **19**, 242–250.
- 78 H. Soliman and M. El-Matbouli, *J. Fish Dis.*, 2018, **41**, 761–772.
- 79 L. Wambua, B. Schneider, A. Okwaro, J. O. Wanga, O. Imali, P. N. Wambua, L. Agutu, C. Olds, C. S. Jones, D. Masiga, C. Midega, Z. Khan, J. Jores and A. Fischer, *Mol. Cell. Probes*, 2017, **35**, 44–56.
- 80 S. Kalsi, M. Valiadi, M. N. Tsaloglou, L. Parry-Jones, A. Jacobs, R. Watson, C. Turner, R. Amos, B. Hadwen, J. Buse, C. Brown, M. Sutton and H. Morgan, *Lab Chip*, 2015, **15**, 3065–3075.
- 81 C. Moody, H. Newell and H. Viljoen, *Biochem. Eng. J.*, 2016, **112**, 193–201.
- 82 D. S. Boyle, D. A. Lehman, L. Lillis, D. Peterson, M. Singhal, N. Armes, M. Parker, O. Piepenburg and J. Overbaugh, *mBio*, 2013, **4**, e00135-13.
- 83 A. Abd El Wahed, A. El-Deeb, M. El-Tholoth, H. Abd El Kader, A. Ahmed, S. Hassan, B. Hoffmann, B. Haas, M. A. Shalaby, F. T. Hufert and M. Weidmann, *PLoS One*, 2013, **8**, e71642.
- 84 R. K. Daher, G. Stewart, M. Boissinot, D. K. Boudreau and M. G. Bergeron, *Mol. Cell. Probes*, 2015, **29**, 116–121.
- 85 N. Yehia, A. S. Arafa, A. Abd El Wahed, A. A. El-Sanousi, M. Weidmann and M. A. Shalaby, *J. Virol. Methods*, 2015, **223**, 45–49.
- 86 L. Lillis, D. A. Lehman, J. B. Siverson, J. Weis, J. Cantera, M. Parker, O. Piepenburg, J. Overbaugh and D. S. Boyle, *J. Virol. Methods*, 2016, **230**, 28–35.
- 87 P. Patel, A. Abd El Wahed, O. Faye, P. Pruger, M. Kaiser, S. Thaloengsok, S. Ubol, A. Sakuntabhai, I. Lepar-Goffart, F. T. Hufert, A. A. Sall, M. Weidmann and M. Niedrig, *PLoS Neglected Trop. Dis.*, 2016, **10**, e0004953.
- 88 M. D. Moore and L. A. Jaykus, *Sci. Rep.*, 2017, **7**, 40244.
- 89 J. Kissenkötter, S. Hansen, S. Böhlken-Fascher, O. G. Ademowo, O. E. Oyinloye, A. S. Bakarey, G. Dobler, D. Tappe, P. Patel, C.-P. Czerny and A. Abd El Wahed, *Anal. Biochem.*, 2017, **544**, 29–33.
- 90 E. S. Yamanaka, L. A. Tortajada-Genaro and Á. Maquieira, *Microchim. Acta*, 2017, **184**, 1453–1462.
- 91 A. Rosser, D. Rollinson, M. Forrest and B. L. Webster, *Parasites Vectors*, 2015, **8**, 446.
- 92 K. Krolov, J. Frolova, O. Tudoran, J. Suhorutsenko, T. Lehto, H. Sibul, I. Mager, M. Laanpere, I. Tulp and U. Langel, *J. Mol. Diagn.*, 2014, **16**, 127–135.
- 93 H. B. Liu, Y. X. Zang, X. J. Du, P. Li and S. Wang, *J. Dairy Sci.*, 2017, **100**, 7016–7025.
- 94 B. Rohrman and R. Richards-Kortum, *Anal. Chem.*, 2015, **87**, 1963–1967.
- 95 C. C. Chao, T. Belinskaya, Z. Zhang and W. M. Ching, *PLoS Neglected Trop. Dis.*, 2015, **9**, e0003884.
- 96 B. Y. C. Ng, E. J. H. Wee, N. P. West and M. Trau, *Sci. Rep.*, 2015, **5**, 15027.



- 97 E. Clancy, O. Higgins, M. S. Forrest, T. W. Boo, M. Cormican, T. Barry, O. Piepenburg and T. J. Smith, *BMC Infect. Dis.*, 2015, **15**, 481.
- 98 H. Y. Lau, Y. Wang, E. J. Wee, J. R. Botella and M. Trau, *Anal. Chem.*, 2016, **88**, 8074–8081.
- 99 K. M. Koo, E. J. Wee, P. N. Mainwaring, Y. Wang and M. Trau, *Small*, 2016, **12**, 6233–6242.
- 100 H. Y. Lau, H. Wu, E. J. Wee, M. Trau, Y. Wang and J. R. Botella, *Sci. Rep.*, 2017, **7**, 38896.
- 101 K. M. Koo, E. J. Wee and M. Trau, *Theranostics*, 2016, **6**, 1415–1424.
- 102 B. Y. C. Ng, E. J. H. Wee, N. P. West and M. Trau, *ACS Sens.*, 2016, **1**, 173–178.
- 103 B. Y. Ng, W. Xiao, N. P. West, E. J. Wee, Y. Wang and M. Trau, *Anal. Chem.*, 2015, **87**, 10613–10618.
- 104 S. Santiago-Felipe, L. A. Tortajada-Genaro, R. Puchades and A. Maquieira, *Anal. Chim. Acta*, 2014, **811**, 81–87.
- 105 Z. Crannell, A. Castellanos-Gonzalez, G. Nair, R. Mejia, A. C. White and R. Richards-Kortum, *Anal. Chem.*, 2016, **88**, 1610–1616.
- 106 M. S. Cordray and R. R. Richards-Kortum, *Malar. J.*, 2015, **14**, 472.
- 107 J. Wang, L. Liu, R. Li, J. Wang, Q. Fu and W. Yuan, *Arch. Virol.*, 2016, **161**, 1015–1018.
- 108 P. A. Tu, J. S. Shiu, S. H. Lee, V. F. Pang, D. C. Wang and P. H. Wang, *J. Virol. Methods*, 2017, **243**, 98–104.
- 109 L. Glais and E. Jacquot, *Methods Mol. Biol.*, 2015, **1302**, 207–225.
- 110 B. Babu, B. K. Washburn, S. H. Miller, K. Poduch, T. Sarigul, G. W. Knox, F. M. Ochoa-Corona and M. L. Paret, *J. Virol. Methods*, 2017, **240**, 78–84.
- 111 M. A. Londono, C. L. Harmon and J. E. Polston, *Virol. J.*, 2016, **13**, 48.
- 112 R. Kapoor, N. Srivastava, S. Kumar, R. K. Saritha, S. K. Sharma, R. K. Jain and V. K. Baranwal, *Arch. Virol.*, 2017, **162**, 2791–2796.
- 113 Q. Liu, B. K. L. Lim, S. Y. Lim, W. Y. Tang, Z. Gu, J. Chung, M. K. Park and T. Barkham, *Sens. Actuators, B*, 2018, **255**, 1595–1603.
- 114 M. L. Powell, F. R. Bowler, A. J. Martinez, C. J. Greenwood, N. Armes and O. Piepenburg, *Anal. Biochem.*, 2017, **543**, 108–115.
- 115 O. A. Saldarriaga, A. Castellanos-Gonzalez, R. Porrozzi, G. C. Baldeviano, A. G. Lescano, M. B. de Los Santos, O. L. Fernandez, N. G. Saravia, E. Costa, P. C. Melby and B. L. Travi, *PLoS Neglected Trop. Dis.*, 2016, **10**, e0004638.
- 116 Y. D. Wu, D. H. Zhou, L. X. Zhang, W. B. Zheng, J. G. Ma, M. Wang, X. Q. Zhu and M. J. Xu, *Parasitol. Res.*, 2016, **115**, 3551–3555.
- 117 C. Escadafal, O. Faye, A. A. Sall, O. Faye, M. Weidmann, O. Strohmeier, F. von Stetten, J. Drexler, M. Eberhard, M. Niedrig and P. Patel, *PLoS Neglected Trop. Dis.*, 2014, **8**, e2730.
- 118 A. J. Saah and D. R. Hoover, *Ann. Intern. Med.*, 1997, **126**, 91–94.
- 119 J. Y. Kim and J.-L. Lee, *J. Food Saf.*, 2016, **36**, 402–411.
- 120 Q. Liu, J. Nam, S. Kim, C. T. Lim, M. K. Park and Y. Shin, *Biosens. Bioelectron.*, 2016, **82**, 1–8.
- 121 D. Mondal, P. Ghosh, M. A. Khan, F. Hossain, S. Bohlken-Fascher, G. Matlashewski, A. Kroeger, P. Olliaro and A. Abd El Wahed, *Parasites Vectors*, 2016, **9**, 281.
- 122 J. Y. Kim and J.-L. Lee, *Food Control*, 2017, **73**(Part B), 1247–1255.
- 123 J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee, P. Essletzbichler, A. J. Dy, J. Joung, V. Verdine, N. Donghia, N. M. Daringer, C. A. Freije, C. Myhrvold, R. P. Bhattacharyya, J. Livny, A. Regev, E. V. Koonin, D. T. Hung, P. C. Sabeti, J. J. Collins and F. Zhang, *Science*, 2017, **356**, 438–442.
- 124 M. Y. Lai, C. H. Ooi and Y. L. Lau, *Am. J. Trop. Med. Hyg.*, 2017, **97**, 1597–1599.
- 125 H. M. Amer, A. Abd El Wahed, M. A. Shalaby, F. N. Almajhdi, F. T. Hufert and M. Weidmann, *J. Virol. Methods*, 2013, **193**, 337–340.
- 126 R. K. Daher, G. Stewart, M. Boissinot and M. G. Bergeron, *Clin. Chem.*, 2014, **60**, 660–666.
- 127 Z. A. Crannell, A. Castellanos-Gonzalez, A. Irani, B. Rohrman, A. C. White and R. Richards-Kortum, *Anal. Chem.*, 2014, **86**, 2565–2571.
- 128 D. S. Boyle, R. Mc Nerney, H. Teng Low, B. T. Leader, A. C. Perez-Osorio, J. C. Meyer, D. M. O'Sullivan, D. G. Brooks, O. Piepenburg and M. S. Forrest, *PLoS One*, 2014, **9**, e103091.
- 129 Z. A. Crannell, M. M. Cabada, A. Castellanos-Gonzalez, A. Irani, A. C. White and R. Richards-Kortum, *Am. J. Trop. Med. Hyg.*, 2015, **92**, 583–587.
- 130 Y. Shin, A. P. Perera, W. Y. Tang, D. L. Fu, Q. Liu, J. K. Sheng, Z. Gu, T. Y. Lee, T. Barkham and M. Kyoung Park, *Biosens. Bioelectron.*, 2015, **68C**, 390–396.
- 131 A. Abd El Wahed, P. Patel, O. Faye, S. Thaloengsok, D. Heidenreich, P. Matangkasombut, K. Manopwisedjaroen, A. Sakuntabhai, A. A. Sall, F. T. Hufert and M. Weidmann, *PLoS One*, 2015, **10**, e0129682.
- 132 G. Nair, M. Rebolledo, A. C. White Jr., Z. Crannell, R. R. Richards-Kortum, A. E. Pinilla, J. D. Ramirez, M. C. Lopez and A. Castellanos-Gonzalez, *Am. J. Trop. Med. Hyg.*, 2015, **93**, 591–595.
- 133 S. A. Ahmed, W. W. van de Sande, M. Desnos-Ollivier, A. H. Fahal, N. A. Mhmoud and G. S. de Hoog, *J. Clin. Microbiol.*, 2015, **53**, 3280–3285.
- 134 O. Faye, O. Faye, B. Soropogui, P. Patel, A. A. El Wahed, C. Loucoubar, G. Fall, D. Kiory, N. Magassouba, S. Keita, M. K. Konde, A. A. Diallo, L. Koivogui, H. Karlberg, A. Mirazimi, O. Nentwich, O. Piepenburg, M. Niedrig, M. Weidmann and A. A. Sall, *Euro. Surveill.*, 2015, **20**, 10–18.
- 135 Y. Yang, X. Qin, G. Wang, Y. Zhang, Y. Shang and Z. Zhang, *Virol. J.*, 2015, **12**, 206.
- 136 Y. Yang, X. Qin, Y. Sun, T. Chen and Z. Zhang, *Virus Genes*, 2016, **52**, 883–886.
- 137 C. Clarke, L. O'Connor, H. Carre-Skinner, O. Piepenburg and T. J. Smith, *BMC Microbiol.*, 2016, **16**, 221–226.
- 138 A. Abd El Wahed, S. S. Sanabani, O. Faye, R. Pessoa, J. V. Patriota, R. R. Giorgi, P. Patel, S. Bohlken-Fascher,



- O. Landt, M. Niedrig, P. M. Zanotto, C. P. Czerny, A. A. Sall and M. Weidmann, *PLoS Curr.*, 2017, **9**, 1–10.
- 139 M. A. Shalaby, A. El-Deeb, M. El-Tholoth, D. Hoffmann, C. P. Czerny, F. T. Hufert, M. Weidmann and A. Abd El Wahed, *BMC Vet. Res.*, 2016, **12**, 244.
- 140 S. Hansen, J. Schafer, K. Fechner, C. P. Czerny and A. Abd El Wahed, *PLoS One*, 2016, **11**, e0168733.
- 141 K. M. Koo, E. J. H. Wee and M. Trau, *Biosens. Bioelectron.*, 2017, **89**, 715–720.
- 142 J. C. Wang, W. Z. Yuan, Q. A. Han, J. F. Wang and L. B. Liu, *J. Virol. Methods*, 2017, **243**, 55–60.
- 143 L. Liu, L. Jiang, Y. Yu, X. Xia, Y. Pan, S. Yan and Y. Wang, *Mol. Cell. Probes*, 2017, **33**, 4–7.
- 144 M. M. Cabada, J. L. Malaga, A. Castellanos-Gonzalez, K. A. Bagwell, P. A. Naeger, H. K. Rogers, S. Maharsi, M. Mbaka and A. C. White Jr., *Am. J. Trop. Med. Hyg.*, 2016, **96**, 341–346.
- 145 Y. Yang, X. Qin, Y. Song, W. Zhang, G. Hu, Y. Dou, Y. Li and Z. Zhang, *Virol. J.*, 2017, **14**, 24.
- 146 M. Si Ammour, G. J. Bilodeau, D. M. Tremblay, H. Van der Heyden, T. Yaseen, L. Varvaro and O. Carisse, *Plant Dis.*, 2017, **101**, 1269–1277.
- 147 J. C. Wang, L. B. Liu, Q. A. Han, J. F. Wang and W. Z. Yuan, *J. Virol. Methods*, 2017, **248**, 145–147.
- 148 Y. Yang, X. Qin, X. Zhang, Z. Zhao, W. Zhang, X. Zhu, G. Cong, Y. Li and Z. Zhang, *Virol. J.*, 2017, **14**, 131.
- 149 J. Wang, J. Wang, R. Li, L. Liu and W. Yuan, *BMC Vet. Res.*, 2017, **13**, 241.
- 150 K. Schlottau, C. M. Freuling, T. Muller, M. Beer and B. Hoffmann, *Virol. J.*, 2017, **14**, 184.
- 151 C. E. Jin, S. S. Yeom, B. Koo, T. Y. Lee, J. H. Lee, Y. Shin and S. B. Lim, *Oncotarget*, 2017, **8**, 83860–83871.
- 152 L. C. Bonney, R. J. Watson, B. Afrough, M. Mullojonova, V. Dzhuraeva, F. Tishkova and R. Hewson, *PLoS Neglected Trop. Dis.*, 2017, **11**, e0006013.
- 153 Y. Geng, J. Wang, L. Liu, Y. Lu, K. Tan and Y.-Z. Chang, *BMC Vet. Res.*, 2017, **13**, 311.
- 154 K. Shahin, J. Gustavo Ramirez-Paredes, G. Harold, B. Lopez-Jimena, A. Adams and M. Weidmann, *PLoS One*, 2018, **13**, e0192979.
- 155 D. Yin, Y. Zhu, K. Wang, J. Wang, X. Zhang, M. Han, Y. He, Q. Chen and G. Hu, *Arch. Virol.*, 2018, **163**, 2459–2463.
- 156 Y. Qi, Q. Yin, Y. Shao, M. Cao, S. Li, H. Chen, W. Shen, J. Rao, J. Li, X. Li, Y. Sun, Y. Lin, Y. Deng, W. Zeng, S. Zheng, S. Liu and Y. Li, *Int. J. Infect. Dis.*, 2018, **70**, 42–50.
- 157 Y. Qi, Q. Yin, Y. Shao, S. Li, H. Chen, W. Shen, J. Rao, J. Li, X. Li, Y. Sun, Y. Lin, Y. Deng, W. Zeng, S. Zheng, S. Liu and Y. Li, *BioMed Res. Int.*, 2018, **2018**, 1–10.
- 158 R. A. Ruehrwein and D. W. Ward, *Soil Sci.*, 1952, **73**, 485–492.
- 159 V. K. La Mer, *Discuss. Faraday Soc.*, 1966, **42**, 248–254.
- 160 T. W. Healy and V. K. La Mer, *J. Colloid Sci.*, 1964, **19**, 323–332.
- 161 R. H. Smellie and V. K. La Mer, *J. Colloid Sci.*, 1958, **13**, 589–599.
- 162 E. J. Wee, H. Y. Lau, J. R. Botella and M. Trau, *Chem. Commun.*, 2015, **51**, 5828–5831.
- 163 E. J. Wee, T. Ha Ngo and M. Trau, *Sci. Rep.*, 2015, **5**, 15028.
- 164 K. M. Koo, E. J. Wee, P. N. Mainwaring and M. Trau, *Sci. Rep.*, 2016, **6**, 30722.
- 165 E. J. H. Wee, T. H. Ngo and M. Trau, *Clin. Epigenet.*, 2015, **7**, 1–9.
- 166 J. S. Del Rio, N. Yehia Adly, J. L. Acero-Sanchez, O. Y. Henry and C. K. O'Sullivan, *Biosens. Bioelectron.*, 2014, **54**, 674–678.
- 167 J. S. Del Rio, M. Svobodova, P. Bustos, P. Conejeros and C. K. O'Sullivan, *Anal. Bioanal. Chem.*, 2016, **408**, 8611–8620.
- 168 M. N. Tsaloglou, A. Nemiroski, G. Camci-Unal, D. C. Christodouleas, L. P. Murray, J. T. Connelly and G. M. Whitesides, *Anal. Biochem.*, 2017, **543**, 116–121.
- 169 R. E. Farrell, in *RNA Methodologies*, ed. R. E. Farrell, Academic Press, San Diego, 4th edn, 2010, ch. 14, pp. 301–320.
- 170 A. Kunze, M. Dilcher, A. Abd El Wahed, F. Hufert, R. Niessner and M. Seidel, *Anal. Chem.*, 2016, **88**, 898–905.
- 171 C. Kober, R. Niessner and M. Seidel, *Biosens. Bioelectron.*, 2018, **100**, 49–55.
- 172 A. Heim, C. Ebnet, G. Harste and P. Pring-Akerblom, *J. Med. Virol.*, 2003, **70**, 228–239.
- 173 W. Bogaerts, P. De Heyn, T. Van Vaerenbergh, K. De Vos, S. K. Selvaraja, T. Claes, P. Dumon, P. Bienstman, D. Van Thourhout and R. Baets, *Laser Photonics Rev.*, 2012, **6**, 47–73.
- 174 B. Koo, C. E. Jin, S. Y. Park, T. Y. Lee, J. Nam, Y. R. Jang, S. M. Kim, J. Y. Kim, S. H. Kim and Y. Shin, *J. Biophotonics*, 2017, **11**, e201700167.
- 175 Y. Shin, A. P. Perera, K. W. Kim and M. K. Park, *Lab Chip*, 2013, **13**, 2106–2114.
- 176 J. Sabaté del Río, T. Steylaerts, O. Y. Henry, P. Bienstman, T. Stakenborg, W. Van Roy and C. K. O'Sullivan, *Biosens. Bioelectron.*, 2015, **73**, 130–137.
- 177 T. N. T. Dao, E. Y. Lee, B. Koo, C. E. Jin, T. Y. Lee and Y. Shin, *Anal. Biochem.*, 2017, **544**, 87–92.
- 178 S. Schlucker, *Angew. Chem., Int. Ed.*, 2014, **53**, 4756–4795.
- 179 J. Wang, K. M. Koo, E. J. Wee, Y. Wang and M. Trau, *Nanoscale*, 2017, **9**, 3496–3503.
- 180 F. Shen, E. K. Davydova, W. Du, J. E. Kreutz, O. Piepenburg and R. F. Ismagilov, *Anal. Chem.*, 2011, **83**, 3533–3540.
- 181 M. N. Tsaloglou, R. J. Watson, C. M. Rushworth, Y. Zhao, X. Niu, J. M. Sutton and H. Morgan, *Analyst*, 2015, **140**, 258–264.
- 182 E.-C. Yeh and L. P. Lee, Presented in part at the 17th International Conference on Miniaturised Systems for Chemistry and Life Sciences, Freiburg, Germany, 27–31 October, 2013.



- 183 E.-C. Yeh, C.-C. Fu, L. Hu, R. Thakur, J. Feng and L. P. Lee, *Sci. Adv.*, 2017, **3**, 1–11.
- 184 Z. Li, Y. Liu, Q. Wei, Y. Liu, W. Liu, X. Zhang and Y. Yu, *PLoS One*, 2016, **11**, e0153359.
- 185 F. Schuler, F. Schwemmer, M. Trotter, S. Wadle, R. Zengerle, F. von Stetten and N. Paust, *Lab Chip*, 2015, **15**, 2759–2766.
- 186 C. J. DeJournette, J. Kim, H. Medlen, X. Li, L. J. Vincent and C. J. Easley, *Anal. Chem.*, 2013, **85**, 10556–10564.
- 187 J. Wang, L. Liu, J. Wang, X. Pang and W. Yuan, *Anal. Biochem.*, 2017, **543**, 122–127.
- 188 S. Santiago-Felipe, L. A. Tortajada-Genaro, S. Morais, R. Puchades and A. Maquieira, *Food Chem.*, 2015, **174**, 509–515.
- 189 H. B. Liu, X. J. Du, Y. X. Zang, P. Li and S. Wang, *J. Agric. Food Chem.*, 2017, **65**, 10290–10299.
- 190 J. Song, C. Liu, M. G. Mauk, S. C. Rankin, J. B. Lok, R. M. Greenberg and H. H. Bau, *Clin. Chem.*, 2017, **63**, 714–722.
- 191 S. Santiago-Felipe, L. A. Tortajada-Genaro, S. Morais, R. Puchades and Á. Maquieira, *Sens. Actuators, B*, 2014, **204**, 273–281.
- 192 S. Kalsi, S. L. Sellars, C. Turner, J. M. Sutton and H. Morgan, *Micromachines*, 2017, **8**, 1–12.
- 193 L. Magro, B. Jacquelin, C. Escadafal, P. Garneret, A. Kwasiborski, J. C. Manuguerra, F. Monti, A. Sakuntabhai, J. Vanhomwegen, P. Lafaye and P. Tabeling, *Sci. Rep.*, 2017, **7**, 1347.
- 194 K. Ming, J. Kim, M. J. Biondi, A. Syed, K. Chen, A. Lam, M. Ostrowski, A. Rebbapragada, J. J. Feld and W. C. Chan, *ACS Nano*, 2015, **9**, 3060–3074.
- 195 J. Kim, M. J. Biondi, J. J. Feld and W. C. W. Chan, *ACS Nano*, 2016, **10**, 4742–4753.
- 196 S. Kersting, V. Rausch, F. F. Bier and M. von Nickisch-Rosenegk, *Mikrochim. Acta*, 2014, **181**, 1715–1723.
- 197 A. Abd El Wahed, M. Weidmann and F. T. Hufert, *J. Clin. Virol.*, 2015, **69**, 16–21.
- 198 M. Branavan, R. E. Mackay, P. Craw, A. Naveenathayalan, J. C. Ahern, T. Sivanesan, C. Hudson, T. Stead, J. Kremer, N. Garg, M. Baker, S. T. Sadiq and W. Balachandran, *Med. Eng. Phys.*, 2016, **38**, 741–748.
- 199 C. Hu, S. Kalsi, I. Zeimpekis, K. Sun, P. Ashburn, C. Turner, J. M. Sutton and H. Morgan, *Biosens. Bioelectron.*, 2017, **96**, 281–287.
- 200 S. Lutz, P. Weber, M. Focke, B. Faltin, J. Hoffmann, C. Muller, D. Mark, G. Roth, P. Munday, N. Armes, O. Piepenburg, R. Zengerle and F. von Stetten, *Lab Chip*, 2010, **10**, 887–893.
- 201 O. Strohmeier, B. Kanat, D. Bär, P. Patel, J. Drexler, M. Weidmann, T. v. Oordt, G. Roth, D. Mark, R. Zengerle and F. v. Stetten, Presented in part at the MicroTAS 2012, Okinawa, Japan, Oct. 28th to Nov. 1st 2012, 2012.
- 202 T. H. Kim, J. Park, C. J. Kim and Y. K. Cho, *Anal. Chem.*, 2014, **86**, 3841–3848.
- 203 G. Silva, J. Oyekanmi, C. K. Nkere, M. Bomer, P. L. Kumar and S. E. Seal, *Anal. Biochem.*, 2018, **546**, 17–22.
- 204 G. Choi, J. H. Jung, B. H. Park, S. J. Oh, J. H. Seo, J. S. Choi, H. Kim do and T. S. Seo, *Lab Chip*, 2016, **16**, 2309–2316.
- 205 G. Choi, J. H. Jung, B. H. Park, S. J. Oh and T. S. Seo, Presented in part at the 19th International Conference on Miniaturized Systems for Chemistry and Life Sciences, Gyeongju, Korea, October 25–29, 2015.

